

Pilot Study of Psilocybin Treatment for Anxiety in Patients

Archives of General Psychiatry

68, 71

DOI: [10.1001/archgenpsychiatry.2010.116](https://doi.org/10.1001/archgenpsychiatry.2010.116)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Current Research on the Human Experience of Spirituality Following the Ingestion of "Magic"™ Psilocybin Mushrooms: An Annotated Bibliography for Social Workers and Other Health Care Professionals. SSRN Electronic Journal, 0, , .	0.4	1
2	Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice. Journal of Psychopharmacology, 2011, 25, 1548-1561.	2.0	135
3	Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology, 2011, 61, 364-381.	2.0	274
4	Hallucinogen Rating Scale (HRS) - Versão brasileira: tradução e adaptação transcultural. Revista De Psiquiatria Clinica, 2011, 38, 231-237.	0.6	8
5	Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. Journal of Psychopharmacology, 2011, 25, 1453-1461.	2.0	641
6	Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology, 2011, 218, 649-665.	1.5	638
7	The Death of Specificity in Psychiatry: cheers or tears?. Perspectives in Biology and Medicine, 2012, 55, 443-460.	0.3	20
8	Shaping the renaissance of psychedelic research. Lancet, The, 2012, 380, 200-201.	6.3	51
9	Research on psychedelic substances. Drug Testing and Analysis, 2012, 4, 539-542.	1.6	3
10	Depression in Medically Ill Patients. Psychiatric Clinics of North America, 2012, 35, 231-247.	0.7	28
11	Psilocybin Biases Facial Recognition, Goal-Directed Behavior, and Mood State Toward Positive Relative to Negative Emotions Through Different Serotonergic Subreceptors. Biological Psychiatry, 2012, 72, 898-906.	0.7	212
12	Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. Journal of Psychopharmacology, 2012, 26, 994-1002.	2.0	420
13	Moral Transhumanism: The Next Step. Journal of Medicine and Philosophy, 2012, 37, 405-416.	0.4	28
14	Amok as viewed by British administrators in colonial Malaya. British Journal of Psychiatry, 2012, 200, 244-244.	1.7	0
16	Therapeutic mechanisms of classic hallucinogens in the treatment of addictions: from indirect evidence to testable hypotheses. Drug Testing and Analysis, 2012, 4, 543-555.	1.6	90
17	Fluorine in psychedelic phenethylamines. Drug Testing and Analysis, 2012, 4, 577-590.	1.6	28
18	Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2138-2143.	3.3	789
19	Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin. British Journal of Psychiatry, 2012, 200, 238-244.	1.7	170

#	ARTICLE	IF	CITATIONS
20	Neuroimaging: A Scanner, Colourfully. <i>Current Biology</i> , 2012, 22, R231-R233.	1.8	2
21	Ayahuasca as Antidepressant? Psychedelics and Styles of Reasoning in Psychiatry. <i>Anthropology of Consciousness</i> , 2012, 23, 44-59.	0.5	23
22	Serotonergic and dopaminergic distinctions in the behavioral pharmacology of (Å±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). <i>Pharmacology Biochemistry and Behavior</i> , 2012, 101, 69-76.	1.3	14
23	Recent developments in mushrooms as anti-cancer therapeutics: a review. <i>3 Biotech</i> , 2012, 2, 1-15.	1.1	266
24	The NMDA antagonist ketamine and the 5-HT agonist psilocybin produce dissociable effects on structural encoding of emotional face expressions. <i>Psychopharmacology</i> , 2013, 225, 227-239.	1.5	70
25	A proposal to evaluate mechanistic efficacy of hallucinogens in addiction treatment. <i>American Journal of Drug and Alcohol Abuse</i> , 2013, 39, 291-297.	1.1	15
26	Psychiatryâ€™s next top model: cause for a re-think on drug models of psychosis and other psychiatric disorders. <i>Journal of Psychopharmacology</i> , 2013, 27, 771-778.	2.0	37
27	Broadband Cortical Desynchronization Underlies the Human Psychedelic State. <i>Journal of Neuroscience</i> , 2013, 33, 15171-15183.	1.7	364
28	Generic legislation of new psychoactive drugs. <i>Journal of Psychopharmacology</i> , 2013, 27, 317-324.	2.0	56
29	Use of the Classic Hallucinogen Psilocybin for Treatment of Existential Distress Associated with Cancer. , 2013, , 291-308.		27
30	Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning. <i>Experimental Brain Research</i> , 2013, 228, 481-491.	0.7	179
31	A survey of hallucinogenic mushroom use, factors related to usage, and perceptions of use among college students. <i>Drug and Alcohol Dependence</i> , 2013, 130, 245-248.	1.6	38
32	Bioactive Alkaloids from Fungi: Psilocybin. , 2013, , 523-552.		6
33	Plant-Based Medicines for Anxiety Disorders, Part 2: A Review of Clinical Studies with Supporting Preclinical Evidence. <i>CNS Drugs</i> , 2013, 27, 301-319.	2.7	111
34	Effects of Schedule I drug laws on neuroscience research and treatment innovation. <i>Nature Reviews Neuroscience</i> , 2013, 14, 577-585.	4.9	239
35	Stimulation of serotonin 2A receptors facilitates consolidation and extinction of fear memory in C57BL/6J mice. <i>Neuropharmacology</i> , 2013, 64, 403-413.	2.0	123
36	PSYCHEDELIC DRUGS, MAGICAL THINKING AND PSYCHOSIS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, e1-e1.	0.9	12
37	Experienced Drug Users Assess the Relative Harms and Benefits of Drugs: A Web-Based Survey. <i>Journal of Psychoactive Drugs</i> , 2013, 45, 322-328.	1.0	37

#	ARTICLE	IF	CITATIONS
38	Hallucinogens. , 2013, , 1-7.		0
39	Ayahuasca and cancer treatment. SAGE Open Medicine, 2013, 1, 205031211350838.	0.7	21
40	Single treatments that have lasting effects: some thoughts on the antidepressant effects of ketamine and botulinum toxin and the anxiolytic effect of psilocybin. Journal of Psychiatry and Neuroscience, 2013, 38, 78-83.	1.4	22
41	Serotonergic hallucinogens as translational models relevant to schizophrenia. International Journal of Neuropsychopharmacology, 2013, 16, 2165-2180.	1.0	51
42	The Psychoactive Effects of Psychiatric Medication: The Elephant in the Room. Journal of Psychoactive Drugs, 2013, 45, 409-415.	1.0	42
43	Fungal Hallucinogens Psilocin, Ibotenic Acid, and Muscimol. Therapeutic Drug Monitoring, 2013, 35, 420-442.	1.0	49
47	The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs. Frontiers in Human Neuroscience, 2014, 8, 20.	1.0	673
48	The Effect of Psilocin on Memory Acquisition, Retrieval, and Consolidation in the Rat. Frontiers in Behavioral Neuroscience, 2014, 8, 180.	1.0	32
49	Neurociencias y aplicaciones psicoterapéuticas en el renacimiento de la investigación con psicodélicos. Revista Chilena De Neuro-Psiquiatria, 2014, 52, 93-102.	0.0	4
50	The effect of acutely administered MDMA on subjective and BOLD-fMRI responses to favourite and worst autobiographical memories. International Journal of Neuropsychopharmacology, 2014, 17, 527-540.	1.0	75
51	The metaphysical combat with death in the terminally ill and the psychedelic trail. Journal of Cancer Research and Therapeutics, 2014, 10, 3.	0.3	110
52	Update on Research-Based Interventions for Anxiety in Patients With Cancer. Clinical Journal of Oncology Nursing, 2014, 18, 5-16.	0.3	8
53	Hallucinogens. , 2014, , 533-552.		3
54	Hallucinogen use predicts reduced recidivism among substance-involved offenders under community corrections supervision. Journal of Psychopharmacology, 2014, 28, 62-66.	2.0	65
55	HERE AND NOW: DISCOVERING THE SACRED WITH ENTHEOGENS. Zygon, 2014, 49, 652-665.	0.2	14
56	Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases. Journal of Nervous and Mental Disease, 2014, 202, 513-520.	0.5	490
57	Potential Therapeutic Effects of Psilocybin/Psilocin are Minimized While Possible Adverse Reactions are Overrated. Therapeutic Drug Monitoring, 2014, 36, 131-132.	1.0	4
58	Correlating the Metabolic Stability of Psychedelic 5-HT2A Agonists with Anecdotal Reports of Human Oral Bioavailability. Neurochemical Research, 2014, 39, 2018-2023.	1.6	26

#	ARTICLE	IF	CITATIONS
59	Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles. <i>Therapeutic Advances in Psychopharmacology</i> , 2014, 4, 156-169.	1.2	99
60	Repeated lysergic acid diethylamide in an animal model of depression: Normalisation of learning behaviour and hippocampal serotonin 5-HT ₂ signalling. <i>Journal of Psychopharmacology</i> , 2014, 28, 545-552.	2.0	56
61	The Heffter Research Institute: Past and Hopeful Future. <i>Journal of Psychoactive Drugs</i> , 2014, 46, 20-26.	1.0	15
62	Psilocybin – Summary of knowledge and new perspectives. <i>European Neuropsychopharmacology</i> , 2014, 24, 342-356.	0.3	167
63	Self-Experimentations with Psychedelics Among Mental Health Professionals: LSD in the Former Czechoslovakia. <i>Journal of Psychoactive Drugs</i> , 2014, 46, 11-19.	1.0	23
64	From Hofmann to the Haight Ashbury, and into the Future: The Past and Potential of Lysergic Acid Diethylamide. <i>Journal of Psychoactive Drugs</i> , 2014, 46, 3-10.	1.0	28
65	Pilot study of the 5-HT _{2A} agonist psilocybin in the treatment of tobacco addiction. <i>Journal of Psychopharmacology</i> , 2014, 28, 983-992.	2.0	613
66	Back to the future: A return to psychedelic treatment models for addiction. <i>Journal of Psychopharmacology</i> , 2014, 28, 981-982.	2.0	10
67	Enhanced repertoire of brain dynamical states during the psychedelic experience. <i>Human Brain Mapping</i> , 2014, 35, 5442-5456.	1.9	298
68	Biosynthesis of N,N-dimethyltryptamine (DMT) in a melanoma cell line and its metabolization by peroxidases. <i>Biochemical Pharmacology</i> , 2014, 88, 393-401.	2.0	14
69	Effect of Psilocin on Extracellular Dopamine and Serotonin Levels in the Mesoaccumbens and Mesocortical Pathway in Awake Rats. <i>Biological and Pharmaceutical Bulletin</i> , 2015, 38, 134-138.	0.6	43
71	The role of serotonin 5-HT _{2A} receptors in memory and cognition. <i>Frontiers in Pharmacology</i> , 2015, 6, 225.	1.6	213
72	Acute Effects of the Novel Psychoactive Drug 2C-B on Emotions. <i>BioMed Research International</i> , 2015, 2015, 1-9.	0.9	28
73	No link found between psychedelics and psychosis. <i>Nature</i> , 2015, , .	13.7	3
74	Ayahuasca psychedelic tested for depression. <i>Nature</i> , 2015, , .	13.7	13
75	Research on Acute Toxicity and the Behavioral Effects of Methanolic Extract from Psilocybin Mushrooms and Psilocin in Mice. <i>Toxins</i> , 2015, 7, 1018-1029.	1.5	35
76	Self-transcendent experience: a grounded theory study. <i>Qualitative Research</i> , 2015, 15, 633-654.	2.2	39
77	User perceptions of mental health consequences of hallucinogen use in self-identified spiritual contexts. <i>NAD Nordic Studies on Alcohol and Drugs</i> , 2015, 32, 545-562.	0.7	4

#	ARTICLE	IF	CITATIONS
78	Psilocybin, psychological distress, and suicidality. <i>Journal of Psychopharmacology</i> , 2015, 29, 1041-1043.	2.0	62
79	Peak experiences and the afterglow phenomenon: When and how do therapeutic effects of hallucinogens depend on psychedelic experiences?. <i>Journal of Psychopharmacology</i> , 2015, 29, 241-253.	2.0	171
80	Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. <i>Journal of Psychopharmacology</i> , 2015, 29, 280-288.	2.0	278
81	Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. <i>Journal of Psychopharmacology</i> , 2015, 29, 289-299.	2.0	768
82	Turn on and tune in to evidence-based psychedelic research. <i>Lancet Psychiatry</i> , the, 2015, 2, 10-12.	3.7	14
83	Long-term use of psychedelic drugs is associated with differences in brain structure and personality in humans. <i>European Neuropsychopharmacology</i> , 2015, 25, 483-492.	0.3	145
84	Psychedelic drugs should be legally reclassified so that researchers can investigate their therapeutic potential. <i>BMJ</i> , The, 2015, 350, h2902-h2902.	3.0	21
85	Psilocybin-induced spiritual experiences and insightfulness are associated with synchronization of neuronal oscillations. <i>Psychopharmacology</i> , 2015, 232, 3663-3676.	1.5	110
86	Neurovascular and neuroimaging effects of the hallucinogenic serotonin receptor agonist psilocin in the rat brain. <i>Neuropharmacology</i> , 2015, 99, 210-220.	2.0	29
87	Bioactive Alkaloids of Hallucinogenic Mushrooms. <i>Studies in Natural Products Chemistry</i> , 2015, , 133-168.	0.8	15
88	Serotonergic Psychedelics Temporarily Modify Information Transfer in Humans. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, .	1.0	67
89	Lysergic Acid Diethylamide and Psilocybin Revisited. <i>Biological Psychiatry</i> , 2015, 78, 516-518.	0.7	13
90	Mechanisms of Action and Persistent Neuroplasticity by Drugs of Abuse. <i>Pharmacological Reviews</i> , 2015, 67, 872-1004.	7.1	125
91	LSD enhances the emotional response to music. <i>Psychopharmacology</i> , 2015, 232, 3607-3614.	1.5	115
92	Psychedelic medicine: a re-emerging therapeutic paradigm. <i>Cmaj</i> , 2015, 187, 1054-1059.	0.9	108
93	Indoleamine Hallucinogens in Cluster Headache: Results of the Clusterbusters Medication Use Survey. <i>Journal of Psychoactive Drugs</i> , 2015, 47, 372-381.	1.0	64
94	Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects. <i>Biological Psychiatry</i> , 2015, 78, 544-553.	0.7	340
95	Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers. <i>Biological Psychiatry</i> , 2015, 78, 572-581.	0.7	206

#	ARTICLE	IF	CITATIONS
96	Forbidden Therapies: Santo Daime, Ayahuasca, and the Prohibition of Entheogens in Western Society. <i>Journal of Religion and Health</i> , 2015, 54, 287-302.	0.8	26
97	LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects. <i>Journal of Psychopharmacology</i> , 2015, 29, 57-68.	2.0	317
98	Recent advances in the neuropsychopharmacology of serotonergic hallucinogens. <i>Behavioural Brain Research</i> , 2015, 277, 99-120.	1.2	221
99	LSD enhances suggestibility in healthy volunteers. <i>Psychopharmacology</i> , 2015, 232, 785-794.	1.5	207
100	Antidepressive and anxiolytic effects of ayahuasca: a systematic literature review of animal and human studies. <i>Revista Brasileira De Psiquiatria</i> , 2016, 38, 65-72.	0.9	98
101	A Model for the Application of Target-Controlled Intravenous Infusion for a Prolonged Immersive DMT Psychedelic Experience. <i>Frontiers in Pharmacology</i> , 2016, 7, 211.	1.6	24
102	Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. <i>Journal of Psychopharmacology</i> , 2016, 30, 1165-1180.	2.0	973
103	Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. <i>Journal of Psychopharmacology</i> , 2016, 30, 1181-1197.	2.0	1,221
104	Psilocybin in end of life care: Implications for further research. <i>Journal of Psychopharmacology</i> , 2016, 30, 1203-1204.	2.0	4
105	Psycho-existential distress in cancer patients: A return to "entheogens". <i>Journal of Psychopharmacology</i> , 2016, 30, 1205-1206.	2.0	11
106	Psilocybin for depression and anxiety associated with life-threatening illnesses. <i>Journal of Psychopharmacology</i> , 2016, 30, 1209-1210.	2.0	14
107	The role of psychedelics in palliative care reconsidered: A case for psilocybin. <i>Journal of Psychopharmacology</i> , 2016, 30, 1212-1214.	2.0	6
108	Psilocybin for anxiety and depression in cancer care? Lessons from the past and prospects for the future. <i>Journal of Psychopharmacology</i> , 2016, 30, 1163-1164.	2.0	14
109	Effect of Hallucinogens on Unconditioned Behavior. <i>Current Topics in Behavioral Neurosciences</i> , 2016, 36, 159-199.	0.8	63
111	Phenomenology, Structure, and Dynamic of Psychedelic States. <i>Current Topics in Behavioral Neurosciences</i> , 2016, 36, 221-256.	0.8	134
112	Therapeutic Applications of Classic Hallucinogens. <i>Current Topics in Behavioral Neurosciences</i> , 2016, 36, 361-391.	0.8	60
113	The serotonergic hallucinogen 5-MeO-DMT disrupts cortical activity in rodents. <i>European Neuropsychopharmacology</i> , 2016, 26, S120-S121.	0.3	2
114	Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. <i>Lancet Psychiatry</i> , 2016, 3, 481-488.	3.7	168

#	ARTICLE	IF	CITATIONS
115	Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. <i>Lancet Psychiatry</i> , 2016, 3, 619-627.	3.7	988
116	Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. <i>European Neuropsychopharmacology</i> , 2016, 26, 1327-1337.	0.3	229
117	LSD modulates music-induced imagery via changes in parahippocampal connectivity. <i>European Neuropsychopharmacology</i> , 2016, 26, 1099-1109.	0.3	95
118	Neural correlates of the LSD experience revealed by multimodal neuroimaging. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 4853-4858.	3.3	586
119	The paradoxical psychological effects of lysergic acid diethylamide (LSD). <i>Psychological Medicine</i> , 2016, 46, 1379-1390.	2.7	222
120	Neuropharmacology of N,N-dimethyltryptamine. <i>Brain Research Bulletin</i> , 2016, 126, 74-88.	1.4	142
121	Clinical applications of hallucinogens: A review.. <i>Experimental and Clinical Psychopharmacology</i> , 2016, 24, 229-268.	1.3	130
122	Measuring the subjective: revisiting the psychometric properties of three rating scales that assess the acute effects of hallucinogens. <i>Human Psychopharmacology</i> , 2016, 31, 356-372.	0.7	34
123	Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. <i>Journal of Psychopharmacology</i> , 2016, 30, 1268-1278.	2.0	303
124	Neurobiology of the Effects of Psilocybin in Relation to Its Potential Therapeutic Targets. , 2016, , 782-793.		8
125	A Profile of Those Who Use Hallucinogenic Mushrooms. , 2016, , 794-800.		3
126	Psilocybin as an Inducer of Ego Death and Similar Experiences of Religious Provenance. , 2016, , 875-889.		0
127	Psilocybin, Lysergic Acid Diethylamide, Mescaline, and Drug-Induced Synesthesia. , 2016, , 890-905.		43
128	The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms. <i>Journal of Psychopharmacology</i> , 2016, 30, 1279-1295.	2.0	175
129	Psychedelics Recruit Multiple Cellular Types and Produce Complex Transcriptional Responses Within the Brain. <i>EBioMedicine</i> , 2016, 11, 262-277.	2.7	53
130	A Public-Health-Based Vision for the Management and Regulation of Psychedelics. <i>Journal of Psychoactive Drugs</i> , 2016, 48, 243-252.	1.0	21
131	Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology. <i>Journal of Psychopharmacology</i> , 2016, 30, 1259-1267.	2.0	251
132	Psychedelics in the treatment of unipolar mood disorders: a systematic review. <i>Journal of Psychopharmacology</i> , 2016, 30, 1220-1229.	2.0	131

#	ARTICLE	IF	CITATIONS
134	Classical hallucinogens and neuroimaging: A systematic review of human studies. <i>Neuroscience and Biobehavioral Reviews</i> , 2016, 71, 715-728.	2.9	79
135	The Evolution of Transcendence. <i>Evolutionary Psychological Science</i> , 2016, 2, 287-307.	0.8	10
136	LSD Acutely Impairs Fear Recognition and Enhances Emotional Empathy and Sociality. <i>Neuropsychopharmacology</i> , 2016, 41, 2638-2646.	2.8	179
137	The current state of research on ayahuasca: A systematic review of human studies assessing psychiatric symptoms, neuropsychological functioning, and neuroimaging. <i>Journal of Psychopharmacology</i> , 2016, 30, 1230-1247.	2.0	85
138	LSD-induced entropic brain activity predicts subsequent personality change. <i>Human Brain Mapping</i> , 2016, 37, 3203-3213.	1.9	240
139	Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 77-81.	0.7	364
140	Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience. <i>European Neuropsychopharmacology</i> , 2016, 26, 756-766.	0.3	97
141	The epistemic innocence of psychedelic states. <i>Consciousness and Cognition</i> , 2016, 39, 28-37.	0.8	28
142	Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years. <i>Therapeutic Advances in Psychopharmacology</i> , 2016, 6, 193-213.	1.2	204
143	Lysergic acid diethylamide: a drug of use? <i>Therapeutic Advances in Psychopharmacology</i> , 2016, 6, 214-228.	1.2	35
144	Exploring Hallucinogen Pharmacology and Psychedelic Medicine with Zebrafish Models. <i>Zebrafish</i> , 2016, 13, 379-390.	0.5	23
145	Psychedelics. <i>Pharmacological Reviews</i> , 2016, 68, 264-355.	7.1	990
146	Decreased mental time travel to the past correlates with default-mode network disintegration under lysergic acid diethylamide. <i>Journal of Psychopharmacology</i> , 2016, 30, 344-353.	2.0	113
147	Ayahuasca: Pharmacology, neuroscience and therapeutic potential. <i>Brain Research Bulletin</i> , 2016, 126, 89-101.	1.4	135
148	Exploring the therapeutic potential of Ayahuasca: acute intake increases mindfulness-related capacities. <i>Psychopharmacology</i> , 2016, 233, 823-829.	1.5	134
149	Zebrafish neurobehavioral phenomics for aquatic neuropharmacology and toxicology research. <i>Aquatic Toxicology</i> , 2016, 170, 297-309.	1.9	106
150	The potential utility of some legal highs in CNS disorders. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2016, 64, 267-274.	2.5	12
151	Analytical characterization of <i>N,N</i> -diethyltryptamine (DALT) and 16 ring-substituted derivatives. <i>Drug Testing and Analysis</i> , 2017, 9, 115-126.	1.6	8

#	ARTICLE	IF	CITATIONS
152	MDMA and PTSD treatment. <i>Neuroscience Letters</i> , 2017, 649, 176-180.	1.0	73
153	Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance. <i>Drug Metabolism Reviews</i> , 2017, 49, 84-91.	1.5	123
154	Pharmacology and Toxicology of N-Benzylphenethylamine (â€œNBOMeâ€) Hallucinogens. <i>Current Topics in Behavioral Neurosciences</i> , 2017, 32, 283-311.	0.8	76
155	The fibrinolytic system: A new target for treatment of depression with psychedelics. <i>Medical Hypotheses</i> , 2017, 100, 46-53.	0.8	29
156	Hallucinogenic Drugs: A New Study Answers Old Questions about LSD. <i>Current Biology</i> , 2017, 27, R156-R158.	1.8	7
157	The association of psychedelic use and opioid use disorders among illicit users in the United States. <i>Journal of Psychopharmacology</i> , 2017, 31, 606-613.	2.0	49
158	Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates. <i>Current Topics in Behavioral Neurosciences</i> , 2017, 36, 393-430.	0.8	152
159	Bioactives from Mushroom and Their Application. , 2017, , 23-57.		26
160	Neuropharmacology of New Psychoactive Substances (NPS). <i>Current Topics in Behavioral Neurosciences</i> , 2017, , .	0.8	17
161	Psilocybin-Assisted Therapy: A Review of a Novel Treatment for Psychiatric Disorders. <i>Journal of Psychoactive Drugs</i> , 2017, 49, 446-455.	1.0	49
162	Why Psychiatry Needs 3,4-Methylenedioxymethamphetamine: A Child Psychiatrist's Perspective. <i>Neurotherapeutics</i> , 2017, 14, 741-749.	2.1	10
163	Patient Experiences of Psilocybin-Assisted Psychotherapy: An Interpretative Phenomenological Analysis. <i>Journal of Humanistic Psychology</i> , 2017, 57, 354-388.	1.4	173
164	The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future. <i>Neuropsychopharmacology</i> , 2017, 42, 2105-2113.	2.8	364
165	Modern Clinical Research on LSD. <i>Neuropsychopharmacology</i> , 2017, 42, 2114-2127.	2.8	146
166	Psychedelics, Personality and Political Perspectives. <i>Journal of Psychoactive Drugs</i> , 2017, 49, 182-191.	1.0	155
167	Drug therapy for symptoms associated with anxiety in adult palliative care patients. <i>The Cochrane Library</i> , 2019, 2019, CD004596.	1.5	7
168	Assessing the Psychedelic â€œAfter-Glowâ€ in Ayahuasca Users: Post-Acute Neurometabolic and Functional Connectivity Changes Are Associated with Enhanced Mindfulness Capacities. <i>International Journal of Neuropsychopharmacology</i> , 2017, 20, 698-711.	1.0	111
169	Cancer at the Dinner Table: Experiences of Psilocybin-Assisted Psychotherapy for the Treatment of Cancer-Related Distress. <i>Journal of Humanistic Psychology</i> , 2017, 57, 488-519.	1.4	94

#	ARTICLE	IF	CITATIONS
170	Patients' Accounts of Increased "Connectedness" and "Acceptance" After Psilocybin for Treatment-Resistant Depression. <i>Journal of Humanistic Psychology</i> , 2017, 57, 520-564.	1.4	309
171	Potential Therapeutic Effects of Psilocybin. <i>Neurotherapeutics</i> , 2017, 14, 734-740.	2.1	180
172	Neuroticism is associated with challenging experiences with psilocybin mushrooms. <i>Personality and Individual Differences</i> , 2017, 117, 155-160.	1.6	54
173	Hypnotic suggestion produces mystical-type experiences in the laboratory: A demonstration proof.. <i>Psychology of Consciousness: Theory Research, and Practice</i> , 2017, 4, 23-37.	0.3	10
174	Acute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects. <i>Translational Psychiatry</i> , 2017, 7, e1084-e1084.	2.4	82
175	Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults. <i>Clinical Pharmacokinetics</i> , 2017, 56, 1543-1554.	1.6	107
176	Psychedelic Drugs in Biomedicine. <i>Trends in Pharmacological Sciences</i> , 2017, 38, 992-1005.	4.0	113
177	Increased thalamic resting-state connectivity as a core driver of LSD-induced hallucinations. <i>Acta Psychiatrica Scandinavica</i> , 2017, 136, 648-657.	2.2	105
178	Does psychedelic drug use reduce risk of suicidality? Evidence from a longitudinal community-based cohort of marginalised women in a Canadian setting. <i>BMJ Open</i> , 2017, 7, e016025.	0.8	39
179	Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. <i>Scientific Reports</i> , 2017, 7, 13187.	1.6	346
180	NATURALIZING PSYCHEDELIC SPIRITUALITY. <i>Zygon</i> , 2017, 52, 623-642.	0.2	10
181	Psychedelic pleasures: An affective understanding of the joys of tripping. <i>International Journal of Drug Policy</i> , 2017, 49, 133-143.	1.6	32
182	Identification of N-Methyl-4-hydroxytryptamine (Norpsilocin) as a Psilocybin Natural Product. <i>Journal of Natural Products</i> , 2017, 80, 2835-2838.	1.5	38
183	Serotonin and brain function: a tale of two receptors. <i>Journal of Psychopharmacology</i> , 2017, 31, 1091-1120.	2.0	440
184	Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow. <i>NeuroImage</i> , 2017, 159, 70-78.	2.1	61
185	Enzymatic Synthesis of Psilocybin. <i>Angewandte Chemie - International Edition</i> , 2017, 56, 12352-12355.	7.2	125
187	Psychedelic drug use in healthy individuals: A review of benefits, costs, and implications for drug policy. <i>Drug Science, Policy and Law</i> , 2017, 3, 205032451772323.	0.6	30
188	Enzymatische Synthese von Psilocybin. <i>Angewandte Chemie</i> , 2017, 129, 12524-12527.	1.6	21

#	ARTICLE	IF	CITATIONS
189	Developing Guidelines and Competencies for the Training of Psychedelic Therapists. Journal of Humanistic Psychology, 2017, 57, 450-487.	1.4	103
190	The Effects of Hallucinogens on Gene Expression. Current Topics in Behavioral Neurosciences, 2017, 36, 137-158.	0.8	33
191	Role of psilocybin in the treatment of depression. Therapeutic Advances in Psychopharmacology, 2017, 7, 54-56.	1.2	25
192	Rational Suicide in the Elderly. , 2017, , .		4
193	Classic Psychedelics and Rational Suicide in the Elderly: Exploring the Potential Utility of a Reemerging Treatment Paradigm. , 2017, , 203-210.		0
194	Of Roots and Fruits: A Comparison of Psychedelic and Nonpsychedelic Mystical Experiences. Journal of Humanistic Psychology, 2017, 57, 338-353.	1.4	53
195	Psychedelics as Medicines: An Emerging New Paradigm. Clinical Pharmacology and Therapeutics, 2017, 101, 209-219.	2.3	202
196	Psilocybin for treating substance use disorders?. Expert Review of Neurotherapeutics, 2017, 17, 203-212.	1.4	56
197	It's time to take psilocybin seriously as a possible treatment for substance use disorders. American Journal of Drug and Alcohol Abuse, 2017, 43, 4-6.	1.1	13
198	Alterations of consciousness and mystical-type experiences after acute LSD in humans. Psychopharmacology, 2017, 234, 1499-1510.	1.5	151
199	5-HT2A Agonists: A Novel Therapy for Functional Neurological Disorders?. International Journal of Neuropsychopharmacology, 2017, 20, 422-427.	1.0	12
200	Perceptions of the medicinal value of hallucinogenic drugs among college students. Journal of Psychedelic Studies, 2017, 1, 50-54.	0.5	6
201	Qualitative and Quantitative Features of Music Reported to Support Peak Mystical Experiences during Psychedelic Therapy Sessions. Frontiers in Psychology, 2017, 8, 1238.	1.1	28
202	Clinical potential of psilocybin as a treatment for mental health conditions. Mental Health Clinician, 2017, 7, 24-28.	0.5	36
204	Ingeniería humana: alterando el cuerpo para ampliar la fantasía moral. Una posible solución a los problemas planteados por Günther Anders.. Daimon, 0, , 31.	0.1	0
205	The Varieties of Self-Transcendent Experience. Review of General Psychology, 2017, 21, 143-160.	2.1	290
206	Psychedelics: Where we are now, why we got here, what we must do. Neuropharmacology, 2018, 142, 7-19.	2.0	96
207	Powerful substances in tiny amounts. NAD Nordic Studies on Alcohol and Drugs, 2018, 35, 39-51.	0.7	114

#	ARTICLE	IF	CITATIONS
208	The hidden therapist: evidence for a central role of music in psychedelic therapy. <i>Psychopharmacology</i> , 2018, 235, 505-519.	1.5	131
209	Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression. <i>Journal of Psychopharmacology</i> , 2018, 32, 811-819.	2.0	97
210	Taking Psychedelics Seriously. <i>Journal of Palliative Medicine</i> , 2018, 21, 417-421.	0.6	91
211	Psychiatry & the psychedelic drugs. Past, present & future. <i>Neuropharmacology</i> , 2018, 142, 200-218.	2.0	222
212	Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression. <i>Neuropharmacology</i> , 2018, 142, 263-269.	2.0	126
213	Lysergic acid diethylamide and psilocybin for the management of patients with persistent pain: a potential role?. <i>Pain Management</i> , 2018, 8, 217-229.	0.7	31
214	Psilocin and ketamine microdosing: effects of subchronic intermittent microdoses in the elevated plus-maze in male Wistar rats. <i>Behavioural Pharmacology</i> , 2018, 29, 530-536.	0.8	33
215	Inside bad trips: Exploring extra-pharmacological factors. <i>Journal of Psychedelic Studies</i> , 2018, 2, 53-60.	0.5	14
216	The use of antidepressants in oncology: a review and practical tips for oncologists. <i>Annals of Oncology</i> , 2018, 29, 101-111.	0.6	48
217	Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease: A systematic review. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 81, 1-10.	2.5	79
218	Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. <i>Journal of Psychopharmacology</i> , 2018, 32, 49-69.	2.0	285
219	The 21st century psychedelic renaissance: heroic steps forward on the back of an elephant. <i>Psychopharmacology</i> , 2018, 235, 551-560.	1.5	49
221	A regulatory perspective on the evaluation of hallucinogen drugs for human use. <i>Neuropharmacology</i> , 2018, 142, 135-142.	2.0	12
222	Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. <i>Psychopharmacology</i> , 2018, 235, 399-408.	1.5	537
223	Pharmacies as potential providers of harm reduction services: A preliminary online survey. <i>Drug Science, Policy and Law</i> , 2018, 4, 205032451876744.	0.6	4
224	Employing Synergistic Interactions of Virtual Reality and Psychedelics in Neuropsychopharmacology. , 2018, , .		3
225	Application of Wild Macrofungi as Anticancer Therapeutics. <i>Fungal Biology</i> , 2018, , 243-274.	0.3	1
226	Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions. <i>International Review of Psychiatry</i> , 2018, 30, 291-316.	1.4	115

#	ARTICLE	IF	CITATIONS
227	Psychiatry might need some psychedelic therapy. <i>International Review of Psychiatry</i> , 2018, 30, 285-290.	1.4	8
228	The influence of therapists' first-hand experience with psychedelics on psychedelic-assisted psychotherapy research and therapist training. <i>Journal of Psychedelic Studies</i> , 2018, 2, 64-73.	0.5	64
229	The moderating effect of psychedelics on the prospective relationship between prescription opioid use and suicide risk among marginalized women. <i>Journal of Psychopharmacology</i> , 2018, 32, 1385-1391.	2.0	22
230	Psychedelics and music: neuroscience and therapeutic implications. <i>International Review of Psychiatry</i> , 2018, 30, 350-362.	1.4	41
231	Awe: a putative mechanism underlying the effects of classic psychedelic-assisted psychotherapy. <i>International Review of Psychiatry</i> , 2018, 30, 331-342.	1.4	98
232	The renaissance in psychedelic research: What do preclinical models have to offer. <i>Progress in Brain Research</i> , 2018, 242, 25-67.	0.9	20
233	More Realistic Forecasting of Future Life Events After Psilocybin for Treatment-Resistant Depression. <i>Frontiers in Psychology</i> , 2018, 9, 1721.	1.1	26
234	Exploring the effect of microdosing psychedelics on creativity in an open-label natural setting. <i>Psychopharmacology</i> , 2018, 235, 3401-3413.	1.5	102
235	Everything old is new again: are psychedelic medicines poised to take mental health by storm?. <i>Acta Psychiatrica Scandinavica</i> , 2018, 138, 365-367.	2.2	0
236	d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders. <i>Progress in Brain Research</i> , 2018, 242, 69-96.	0.9	61
237	Psychedelic use and intimate partner violence: The role of emotion regulation. <i>Journal of Psychopharmacology</i> , 2018, 32, 749-755.	2.0	35
238	A Survey of American Psychiatrists' Attitudes Toward Classic Hallucinogens. <i>Journal of Nervous and Mental Disease</i> , 2018, 206, 476-480.	0.5	47
239	High dose psilocybin is associated with positive subjective effects in healthy volunteers. <i>Journal of Psychopharmacology</i> , 2018, 32, 770-778.	2.0	46
240	Mental health of a self-selected sample of psychedelic users and self-medication practices with psychedelics. <i>Journal of Psychedelic Studies</i> , 2018, 2, 45-52.	0.5	15
241	Positive psychology in the investigation of psychedelics and entactogens: A critical review. <i>Neuropharmacology</i> , 2018, 142, 179-199.	2.0	39
242	Unifying Theories of Psychedelic Drug Effects. <i>Frontiers in Pharmacology</i> , 2018, 9, 172.	1.6	107
243	Neuroendocrine Associations Underlying the Persistent Therapeutic Effects of Classic Serotonergic Psychedelics. <i>Frontiers in Pharmacology</i> , 2018, 9, 177.	1.6	29
244	Individual Experiences in Four Cancer Patients Following Psilocybin-Assisted Psychotherapy. <i>Frontiers in Pharmacology</i> , 2018, 9, 256.	1.6	62

#	ARTICLE	IF	CITATIONS
245	Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development. <i>Frontiers in Pharmacology</i> , 2018, 9, 733.	1.6	115
246	N, N-Dimethyltryptamine (DMT), an Endogenous Hallucinogen: Past, Present, and Future Research to Determine Its Role and Function. <i>Frontiers in Neuroscience</i> , 2018, 12, 536.	1.4	90
247	Biocatalytic Production of Psilocybin and Derivatives in Tryptophan Synthase-Enhanced Reactions. <i>Chemistry - A European Journal</i> , 2018, 24, 10028-10031.	1.7	29
248	Iterative α -tryptophan Methylation in <i>Psilocybe</i> Evolved by Subdomain Duplication. <i>ChemBioChem</i> , 2018, 19, 2160-2166.	1.3	16
249	Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 889-902.	1.3	134
250	Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress. <i>International Review of Psychiatry</i> , 2018, 30, 317-330.	1.4	47
251	DMT Models the Near-Death Experience. <i>Frontiers in Psychology</i> , 2018, 9, 1424.	1.1	122
252	Psychedelic therapy as a complementary treatment approach for alcohol use disorders. <i>Journal of Psychedelic Studies</i> , 2018, 2, 36-44.	0.5	0
253	The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. <i>Neuropharmacology</i> , 2018, 142, 143-166.	2.0	184
254	Psychedelics Promote Structural and Functional Neural Plasticity. <i>Cell Reports</i> , 2018, 23, 3170-3182.	2.9	566
255	Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. <i>Psychological Medicine</i> , 2019, 49, 655-663.	2.7	479
256	The influence of ketamine on drug discovery in depression. <i>Drug Discovery Today</i> , 2019, 24, 2033-2043.	3.2	57
257	Microdosing psychedelics: More questions than answers? An overview and suggestions for future research. <i>Journal of Psychopharmacology</i> , 2019, 33, 1039-1057.	2.0	121
258	Classical psychedelics for the treatment of depression and anxiety: A systematic review. <i>Journal of Affective Disorders</i> , 2019, 258, 11-24.	2.0	124
259	Serotonergic hallucinogens/psychedelics could be promising treatments for depressive and anxiety disorders in end-stage cancer. <i>BMC Psychiatry</i> , 2019, 19, 321.	1.1	11
260	Toward a contextual psychedelic-assisted therapy: Perspectives from Acceptance and Commitment Therapy and contextual behavioral science. <i>Journal of Contextual Behavioral Science</i> , 2019, 14, 136-145.	1.3	25
261	The psychedelic renaissance and the limitations of a White-dominant medical framework: A call for indigenous and ethnic minority inclusion. <i>Journal of Psychedelic Studies</i> , 2019, 4, 4-15.	0.5	113
262	In vivo production of psilocybin in <i>E. coli</i> . <i>Metabolic Engineering</i> , 2019, 56, 111-119.	3.6	42

#	ARTICLE	IF	CITATIONS
263	Psilocybin for depression: Considerations for clinical trial design. <i>Journal of Psychedelic Studies</i> , 2019, 3, 269-279.	0.5	6
264	Neurochemical models of near-death experiences: A large-scale study based on the semantic similarity of written reports. <i>Consciousness and Cognition</i> , 2019, 69, 52-69.	0.8	48
265	Dynamical exploration of the repertoire of brain networks at rest is modulated by psilocybin. <i>NeuroImage</i> , 2019, 199, 127-142.	2.1	152
266	Psychedelic-assisted therapies: The past, and the need to move forward responsibly. <i>International Journal of Drug Policy</i> , 2019, 70, 94-98.	1.6	10
267	REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics. <i>Pharmacological Reviews</i> , 2019, 71, 316-344.	7.1	467
268	Enzymatic Route toward 6-Methylated Baeocystin and Psilocybin. <i>ChemBioChem</i> , 2019, 20, 2824-2829.	1.3	17
269	Replication and extension of a model predicting response to psilocybin. <i>Psychopharmacology</i> , 2019, 236, 3221-3230.	1.5	49
270	Immunomodulatory Aspects of Medicinal Mushrooms. , 2019, , 169-185.		0
271	Identity Narrative and Its Role in Biological Survival: Implications for Child and Adolescent Psychotherapy. <i>Journal of Infant, Child, and Adolescent Psychotherapy</i> , 2019, 18, 155-184.	0.4	5
272	Cessation and reduction in alcohol consumption and misuse after psychedelic use. <i>Journal of Psychopharmacology</i> , 2019, 33, 1088-1101.	2.0	145
273	Rapid-acting antidepressants. <i>Advances in Pharmacology</i> , 2019, 86, 47-96.	1.2	49
274	Mushroom Toxins: Chemistry and Toxicology. <i>Journal of Agricultural and Food Chemistry</i> , 2019, 67, 5053-5071.	2.4	31
275	Psychedelic-assisted therapy for anxiety and depression in the face of death: A critical review with an anthropological lens. <i>Journal of Psychedelic Studies</i> , 2019, 3, 14-18.	0.5	1
276	Beyond LSD: A Broader Psychedelic Zeitgeist during the Early to Mid-20 th Century. <i>Journal of Psychoactive Drugs</i> , 2019, 51, 210-217.	1.0	9
277	Classic psychedelics: the special role of the visual system. <i>Reviews in the Neurosciences</i> , 2019, 30, 651-669.	1.4	6
278	Descriptive assemblage of psychedelic microdosing: Netnographic study of Youtubeâ„¢ videos and on-going research projects. <i>Performance Enhancement and Health</i> , 2019, 6, 129-138.	0.8	17
279	Comparison of the behavioral effects of mescaline analogs using the head twitch response in mice. <i>Journal of Psychopharmacology</i> , 2019, 33, 406-414.	2.0	18
280	Psychedelic therapy in the Czech Republic: A theoretical concept or a realistic goal?. <i>Journal of Psychedelic Studies</i> , 2019, 3, 19-31.	0.5	5

#	ARTICLE	IF	CITATIONS
281	Sub-Acute Effects of Psilocybin on Empathy, Creative Thinking, and Subjective Well-Being. <i>Journal of Psychoactive Drugs</i> , 2019, 51, 123-134.	1.0	91
282	Pharmacotherapy of anxiety disorders in the 21st century: A call for novel approaches. <i>Annals of General Psychiatry</i> , 2019, 32, e100136.	1.1	7
283	Seeing without self: Discovering new meaning with psychedelic-assisted psychotherapy. <i>Neuropsychoanalysis</i> , 2019, 21, 53-78.	0.1	18
285	Hallucinogens and Their Therapeutic Use: A Literature Review. <i>Journal of Psychiatric Practice</i> , 2019, 25, 334-346.	0.3	9
286	“Go Ask Alice”: The Case for Researching Schedule I Drugs. <i>Cambridge Quarterly of Healthcare Ethics</i> , 2019, 28, 168-177.	0.5	2
287	Trait Openness and serotonin 2A receptors in healthy volunteers: A positron emission tomography study. <i>Human Brain Mapping</i> , 2019, 40, 2117-2124.	1.9	8
288	How do psychedelics work?. <i>Current Opinion in Psychiatry</i> , 2019, 32, 16-21.	3.1	73
289	Theranostic pharmacology in PTSD: Neurobiology and timing. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 90, 245-263.	2.5	7
290	Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. , 2019, 197, 83-102.		296
291	Ceremonial “Plant Medicine”™ use and its relationship to recreational drug use: an exploratory study. <i>Addiction Research and Theory</i> , 2019, 27, 68-75.	1.2	14
292	Can Psychedelic Drugs Attenuate Age-Related Changes in Cognition and Affect?. <i>Journal of Cognitive Enhancement: Towards the Integration of Theory and Practice</i> , 2020, 4, 219-227.	0.8	12
293	DARK Classics in Chemical Neuroscience: NBOMes. <i>ACS Chemical Neuroscience</i> , 2020, 11, 3860-3869.	1.7	39
294	Ayahuasca™s “afterglow™”: improved mindfulness and cognitive flexibility in ayahuasca drinkers. <i>Psychopharmacology</i> , 2020, 237, 1161-1169.	1.5	72
295	Social Work and Psychedelic-Assisted Therapies: Practice Considerations for Breakthrough Treatments. <i>Clinical Social Work Journal</i> , 2021, 49, 356-367.	1.3	6
296	The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis. <i>Psychiatry Research</i> , 2020, 284, 112749.	1.7	104
297	An Improved, Practical, and Scalable Five-Step Synthesis of Psilocybin. <i>Synthesis</i> , 2020, 52, 688-694.	1.2	12
298	Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species. <i>Neuropharmacology</i> , 2020, 167, 107933.	2.0	132
299	Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. <i>Journal of Psychopharmacology</i> , 2020, 34, 155-166.	2.0	171

#	ARTICLE	IF	CITATIONS
300	Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers. <i>Psychopharmacology</i> , 2020, 237, 841-853.	1.5	83
301	Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials. <i>Frontiers in Psychiatry</i> , 2019, 10, 943.	1.3	80
302	Therapeutic use of serotonergic hallucinogens: A review of the evidence and of the biological and psychological mechanisms. <i>Neuroscience and Biobehavioral Reviews</i> , 2020, 108, 423-434.	2.9	82
303	Population Survey Data Informing the Therapeutic Potential of Classic and Novel Phenethylamine, Tryptamine, and Lysergamide Psychedelics. <i>Frontiers in Psychiatry</i> , 2019, 10, 896.	1.3	28
304	Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study. <i>EClinicalMedicine</i> , 2020, 27, 100538.	3.2	138
305	Microdosing psychedelics: Subjective benefits and challenges, substance testing behavior, and the relevance of intention. <i>Journal of Psychopharmacology</i> , 2022, 36, 85-96.	2.0	25
306	MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study. <i>Scientific Reports</i> , 2020, 10, 20442.	1.6	70
307	Advancing elite athlete mental health treatment with psychedelic-assisted psychotherapy. <i>Journal of Applied Sport Psychology</i> , 2020, , 1-19.	1.4	1
308	The Effects of Daytime Psilocybin Administration on Sleep: Implications for Antidepressant Action. <i>Frontiers in Pharmacology</i> , 2020, 11, 602590.	1.6	11
309	Propri�t�s �golytiques des psych�d�liques et int�r�ts dans le traitement de la d�pression. <i>Psychologie Francaise</i> , 2020, 66, 303-303.	0.2	0
310	Metabolizing Death: Re-Thinking Recovery from Substance Use Disorder through the Creative Cartographies of William James and Ernest Becker. <i>Pastoral Psychology</i> , 2020, 69, 169-186.	0.4	0
311	At the Intersection of Palliative Care, Psychedelic Medicine, and Healthcare Reform: A Call for a New Hospice and Palliative Care Movement. <i>Journal of Palliative Care</i> , 2020, , 082585972094689.	0.4	1
312	Psychedelics and virtual reality: parallels and applications. <i>Therapeutic Advances in Psychopharmacology</i> , 2020, 10, 204512532094835.	1.2	15
313	Post-Psychedelic Reductions in Experiential Avoidance Are Associated With Decreases in Depression Severity and Suicidal Ideation. <i>Frontiers in Psychiatry</i> , 2020, 11, 782.	1.3	54
314	Addressing fear of death and dying: traditional and innovative interventions. <i>Mortality</i> , 2022, 27, 18-37.	0.3	6
315	The emerging role of psilocybin and MDMA in the treatment of mental illness. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 1263-1273.	1.4	29
316	Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. <i>Nature Reviews Neuroscience</i> , 2020, 21, 611-624.	4.9	244
317	Psilocybin as a New Approach to Treat Depression and Anxiety in the Context of Life-Threatening Diseases�� A Systematic Review and Meta-Analysis of Clinical Trials. <i>Biomedicine</i> , 2020, 8, 331.	1.4	51

#	ARTICLE	IF	CITATIONS
318	Psychedelic Treatments for Psychiatric Disorders: A Systematic Review and Thematic Synthesis of Patient Experiences in Qualitative Studies. <i>CNS Drugs</i> , 2020, 34, 925-946.	2.7	87
319	Medical Stress and Fear of Death and Dying in a Medical Patient Population. <i>Omega: Journal of Death and Dying</i> , 2020, , 003022282096692.	0.7	0
320	The History of Psychedelics in Psychiatry. <i>Pharmacopsychiatry</i> , 2021, 54, 151-166.	1.7	55
321	The potential synergistic effects between psychedelic administration and nature contact for the improvement of mental health. <i>Health Psychology Open</i> , 2020, 7, 205510292097812.	0.7	32
324	Psychedelic-assisted therapy for functional neurological disorders: A theoretical framework and review of prior reports. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00688.	1.1	8
325	Toxicology and Analysis of Psychoactive Tryptamines. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9279.	1.8	29
326	Post-acute psychological effects of classical serotonergic psychedelics: a systematic review and meta-analysis. <i>Psychological Medicine</i> , 2020, 50, 2655-2666.	2.7	33
327	Psychedelic treatment of functional neurological disorder: a systematic review. <i>Therapeutic Advances in Psychopharmacology</i> , 2020, 10, 204512532091212.	1.2	21
328	The Psilocin (4-hydroxy-N,N-dimethyltryptamine) and Bufotenine (5-hydroxy-N,N-dimethyltryptamine) Case: Ensuring the Correct Isomer has Been Identified. <i>Journal of Forensic Sciences</i> , 2020, 65, 1450-1457.	0.9	8
329	Chronic pain and psychedelics: a review and proposed mechanism of action. <i>Regional Anesthesia and Pain Medicine</i> , 2020, 45, 486-494.	1.1	62
330	Psilocybin: from ancient magic to modern medicine. <i>Journal of Antibiotics</i> , 2020, 73, 679-686.	1.0	72
331	Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 655-670.	1.3	41
332	Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin. <i>Neuropsychopharmacology</i> , 2020, 45, 2003-2011.	2.8	127
333	Compassionate use of psychedelics. <i>Medicine, Health Care and Philosophy</i> , 2020, 23, 485-496.	0.9	10
334	Automated detection of the head-twitch response using wavelet scalograms and a deep convolutional neural network. <i>Scientific Reports</i> , 2020, 10, 8344.	1.6	27
335	A Meta-Analysis of Placebo-Controlled Trials of Psychedelic-Assisted Therapy. <i>Journal of Psychoactive Drugs</i> , 2020, 52, 289-299.	1.0	89
336	Psilocybin occasioned mystical-type experiences. <i>Human Psychopharmacology</i> , 2020, 35, e2742.	0.7	16
337	Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials. <i>Psychopharmacology</i> , 2020, 237, 2485-2497.	1.5	103

#	ARTICLE	IF	CITATIONS
338	Mystical Experiences in Retrospective Reports of First Times Using a Psychedelic in Finland. <i>Journal of Psychoactive Drugs</i> , 2020, 52, 309-318.	1.0	18
339	Taxonomic identification and bioactive compounds characterization of <i>Psilocybe cubensis</i> DPT1 to probe its antibacterial and mosquito larvicidal competency. <i>Microbial Pathogenesis</i> , 2020, 143, 104138.	1.3	11
340	Long-term effects of psychedelic drugs: A systematic review. <i>Neuroscience and Biobehavioral Reviews</i> , 2020, 113, 179-189.	2.9	96
341	Tripping on nothing: placebo psychedelics and contextual factors. <i>Psychopharmacology</i> , 2020, 237, 1371-1382.	1.5	78
342	How does ayahuasca work from a psychiatric perspective? Pros and cons of the entheogenic therapy. <i>Human Psychopharmacology</i> , 2020, 35, e2728.	0.7	11
343	Reviewing the Potential of Psychedelics for the Treatment of PTSD. <i>International Journal of Neuropsychopharmacology</i> , 2020, 23, 385-400.	1.0	106
344	Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities. <i>Journal of Psychopharmacology</i> , 2020, 34, 612-622.	2.0	36
345	A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neocortical 5-HT _{2A} receptor binding. <i>European Neuropsychopharmacology</i> , 2020, 33, 71-80.	0.3	88
346	Psychedelics, but Not Ketamine, Produce Persistent Antidepressant-like Effects in a Rodent Experimental System for the Study of Depression. <i>ACS Chemical Neuroscience</i> , 2020, 11, 864-871.	1.7	114
347	Active Metabolite of Aeruginascin (4-Hydroxy- <i>N,N,N</i> -trimethyltryptamine): Synthesis, Structure, and Serotonergic Binding Affinity. <i>ACS Omega</i> , 2020, 5, 16940-16943.	1.6	21
348	Direct Phosphorylation of Psilocin Enables Optimized cGMP Kilogram-Scale Manufacture of Psilocybin. <i>ACS Omega</i> , 2020, 5, 16959-16966.	1.6	20
349	Altered states of consciousness and creativity. , 2020, , 121-158.		19
350	Historic psychedelic drug trials and the treatment of anxiety disorders. <i>Depression and Anxiety</i> , 2020, 37, 1261-1279.	2.0	23
351	Psychedelics and Psychedelic-Assisted Psychotherapy. <i>American Journal of Psychiatry</i> , 2020, 177, 391-410.	4.0	309
352	Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey. <i>Frontiers in Psychiatry</i> , 2019, 10, 955.	1.3	75
353	Psilocybin Induces Time-Dependent Changes in Global Functional Connectivity. <i>Biological Psychiatry</i> , 2020, 88, 197-207.	0.7	104
354	A dangerous method? Psychedelic therapy at Modum Bad, Norway, 1961-1976. <i>History of Psychiatry</i> , 2020, 31, 217-226.	0.1	8
355	Classic psychedelics as therapeutics for psychiatric disorders. <i>Handbook of Behavioral Neuroscience</i> , 2020, 31, 959-966.	0.7	4

#	ARTICLE	IF	CITATIONS
356	Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression. <i>Journal of Psychopharmacology</i> , 2020, 34, 167-180.	2.0	92
358	Learning to Let Go: A Cognitive-Behavioral Model of How Psychedelic Therapy Promotes Acceptance. <i>Frontiers in Psychiatry</i> , 2020, 11, 5.	1.3	84
359	A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses. <i>Journal of the Neurological Sciences</i> , 2020, 411, 116715.	0.3	52
360	Inhaled 5-methoxy-N,N-dimethyltryptamine: Supportive context associated with positive acute and enduring effects. <i>Journal of Psychedelic Studies</i> , 2020, 4, 114-122.	0.5	14
361	Psychedelics and psychological flexibility – Results of a prospective web-survey using the Acceptance and Action Questionnaire II. <i>Journal of Contextual Behavioral Science</i> , 2020, 16, 37-44.	1.3	28
362	Whispering Hypnosis: Phylogenetically Programmed Behavior and a Pluralistic Understanding of Hypnosis. <i>American Journal of Clinical Hypnosis</i> , 2020, 62, 178-197.	0.3	0
363	Serotonin and serotonin receptors in hallucinogen action. <i>Handbook of Behavioral Neuroscience</i> , 2020, 31, 843-863.	0.7	2
364	Metabolic engineering of <i>Saccharomyces cerevisiae</i> for the de novo production of psilocybin and related tryptamine derivatives. <i>Metabolic Engineering</i> , 2020, 60, 25-36.	3.6	62
365	Dynamic coupling of whole-brain neuronal and neurotransmitter systems. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 9566-9576.	3.3	173
366	Defining the Roles and Research Priorities for Psychedelic-Assisted Therapies in Patients with Serious Illness: Expert Clinicians' and Investigators' Perspectives. <i>Journal of Palliative Medicine</i> , 2020, 23, 1323-1334.	0.6	22
367	Experience of Music Used With Psychedelic Therapy: A Rapid Review and Implications. <i>Journal of Music Therapy</i> , 2020, 57, 282-314.	0.6	15
368	Depression, Mindfulness, and Psilocybin: Possible Complementary Effects of Mindfulness Meditation and Psilocybin in the Treatment of Depression. A Review. <i>Frontiers in Psychiatry</i> , 2020, 11, 224.	1.3	37
369	Subacute effects of the psychedelic ayahuasca on the salience and default mode networks. <i>Journal of Psychopharmacology</i> , 2020, 34, 623-635.	2.0	52
370	Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder. <i>JAMA Psychiatry</i> , 2021, 78, 481.	6.0	648
371	Transcriptional regulation in the rat prefrontal cortex and hippocampus after a single administration of psilocybin. <i>Journal of Psychopharmacology</i> , 2021, 35, 483-493.	2.0	52
372	Tryptophan Synthase: Biocatalyst Extraordinaire. <i>ChemBioChem</i> , 2021, 22, 5-16.	1.3	47
373	Making “bad trips” good: How users of psychedelics narratively transform challenging trips into valuable experiences. <i>International Journal of Drug Policy</i> , 2021, 87, 102997.	1.6	68
374	Acute subjective effects in LSD- and MDMA-assisted psychotherapy. <i>Journal of Psychopharmacology</i> , 2021, 35, 362-374.	2.0	38

#	ARTICLE	IF	CITATIONS
375	Psilocybin exerts distinct effects on resting state networks associated with serotonin and dopamine in mice. <i>NeuroImage</i> , 2021, 225, 117456.	2.1	25
376	Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin. <i>Neurotherapeutics</i> , 2021, 18, 534-543.	2.1	54
377	Ketamine and Serotonergic Psychedelics: Common Mechanisms Underlying the Effects of Rapid-Acting Antidepressants. <i>International Journal of Neuropsychopharmacology</i> , 2021, 24, 8-21.	1.0	58
378	Effects of a single dose of psilocybin on behaviour, brain 5-HT _{2A} receptor occupancy and gene expression in the pig. <i>European Neuropsychopharmacology</i> , 2021, 42, 1-11.	0.3	19
379	Development and validation of an LC-MS/MS method for the bioanalysis of psilocybin's main metabolites, psilocin and 4-hydroxyindole-3-acetic acid, in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021, 1164, 122486.	1.2	26
380	Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms. <i>Pharmacological Reviews</i> , 2021, 73, 202-277.	7.1	110
381	Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies. <i>Acta Psychiatrica Scandinavica</i> , 2021, 143, 101-118.	2.2	137
382	Who is the typical psychedelics user? Methodological challenges for research in psychedelics use and its consequences. <i>NAD Nordic Studies on Alcohol and Drugs</i> , 2021, 38, 35-49.	0.7	11
383	Efficacy of Psychoactive Drugs for the Treatment of Posttraumatic Stress Disorder: A Systematic Review of MDMA, Ketamine, LSD and Psilocybin. <i>Journal of Psychoactive Drugs</i> , 2021, 53, 85-95.	1.0	23
384	Within-treatment changes in a novel addiction treatment program using traditional Amazonian medicine. <i>Therapeutic Advances in Psychopharmacology</i> , 2021, 11, 204512532098663.	1.2	12
385	Psychedelic Medicines in Major Depression: Progress and Future Challenges. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1305, 515-533.	0.8	3
386	Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing. <i>Scientific Reports</i> , 2021, 11, 1941.	1.6	76
387	Psychedelics, placebo effects, and set and setting: Insights from common factors theory of psychotherapy. <i>Transcultural Psychiatry</i> , 2022, 59, 652-664.	0.9	61
388	Psychedelics and Psychedelic-Assisted Psychotherapy. <i>Focus (American Psychiatric Publishing)</i> , 2021, 19, 95-115.	0.4	6
389	Psychedelic Drugs. , 2021, , 1-8.		0
390	Biosynthesis and synthetic biology of psychoactive natural products. <i>Chemical Society Reviews</i> , 2021, 50, 6950-7008.	18.7	32
391	Tripping over the other: Could psychedelics increase empathy?. <i>Journal of Evolutionary Psychology</i> , 2021, 4, 163-170.	1.4	11
392	Therapeutic Use of Hallucinogens. , 2021, , 479-510.		0

#	ARTICLE	IF	CITATIONS
393	Behavioral arrest and a characteristic slow waveform are hallmark responses to selective 5-HT2A receptor activation. <i>Scientific Reports</i> , 2021, 11, 1925.	1.6	9
394	What is the clinical evidence on psilocybin for the treatment of psychiatric disorders? A systematic review. <i>Porto Biomedical Journal</i> , 2021, 6, e128.	0.4	15
395	Antidepressant Drugs. , 2021, , .		0
396	Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches. <i>Journal of Psychopharmacology</i> , 2021, 35, 353-361.	2.0	49
398	Recent developments in geriatric psychopharmacology. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 341-355.	1.3	0
399	Development and Evaluation of a Therapist Training Program for Psilocybin Therapy for Treatment-Resistant Depression in Clinical Research. <i>Frontiers in Psychiatry</i> , 2021, 12, 586682.	1.3	38
401	Dose-response relationships of psilocybin-induced subjective experiences in humans. <i>Journal of Psychopharmacology</i> , 2021, 35, 384-397.	2.0	38
402	Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 553-562.	2.5	64
403	Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action. <i>Journal of Psychopharmacology</i> , 2021, 35, 453-458.	2.0	30
404	Psychedelic Communitas: Intersubjective Experience During Psychedelic Group Sessions Predicts Enduring Changes in Psychological Wellbeing and Social Connectedness. <i>Frontiers in Pharmacology</i> , 2021, 12, 623985.	1.6	95
405	Naturalistic Use of Mescaline Is Associated with Self-Reported Psychiatric Improvements and Enduring Positive Life Changes. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 543-552.	2.5	58
406	LSD et soins palliatifs dans les années 1960, un rendez-vous manqué?. <i>Medecine Palliative</i> , 2021, 20, 312-312.	0.0	1
407	Whitewashing psychedelics: racial equity in the emerging field of psychedelic-assisted mental health research and treatment. <i>Drugs: Education, Prevention and Policy</i> , 2021, 28, 211-214.	0.8	23
408	Effectiveness of Psilocybin on Depression: A Qualitative Study. <i>Electronic Journal of General Medicine</i> , 2021, 18, em296.	0.3	5
409	Psilocybin and MDMA for the treatment of trauma-related psychopathology. <i>International Review of Psychiatry</i> , 2021, 33, 229-249.	1.4	46
410	Psilocybin: From Serendipity to Credibility?. <i>Frontiers in Psychiatry</i> , 2021, 12, 659044.	1.3	20
412	Mapping an Agenda for Psychedelic-Assisted Therapy Research in Patients with Serious Illness. <i>Journal of Palliative Medicine</i> , 2021, 24, 1657-1666.	0.6	14
413	Trial of Psilocybin versus Escitalopram for Depression. <i>New England Journal of Medicine</i> , 2021, 384, 1402-1411.	13.9	643

#	ARTICLE	IF	CITATIONS
414	Clinical and biological predictors of psychedelic response in the treatment of psychiatric and addictive disorders: A systematic review. <i>Journal of Psychiatric Research</i> , 2021, 137, 273-282.	1.5	41
415	Amazonian Medicine and the Psychedelic Revival: Considering the "Dieta". <i>Frontiers in Pharmacology</i> , 2021, 12, 639124.	1.6	9
416	Psychedelics and health behaviour change. <i>Journal of Psychopharmacology</i> , 2022, 36, 12-19.	2.0	40
417	Tolerance to neurochemical and behavioral effects of the hallucinogen 25I-NBOMe. <i>Psychopharmacology</i> , 2021, 238, 2349-2364.	1.5	15
418	Day trip to hell: A mixed methods study of challenging psychedelic experiences. <i>Journal of Psychedelic Studies</i> , 2021, 5, 114-127.	0.5	17
419	The Therapeutic Potential of Psilocybin. <i>Molecules</i> , 2021, 26, 2948.	1.7	78
420	Psychedelics as Reemerging Treatments for Anxiety Disorders: Possibilities and Challenges in a Nascent Field. <i>Focus (American Psychiatric Publishing)</i> , 2021, 19, 190-196.	0.4	2
421	CE: Psychedelic-Assisted Therapy. <i>American Journal of Nursing</i> , 2021, 121, 34-40.	0.2	15
422	Ayahuasca Improves Self-perception of Speech Performance in Subjects With Social Anxiety Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 540-550.	0.7	42
424	Promising Anti-cancer Therapeutics From Mushrooms: Current Findings and Future Perceptions. <i>Current Pharmaceutical Biotechnology</i> , 2021, 22, 1164-1191.	0.9	4
425	Turn on, Tune in, and Drop out: Predictors of Attrition in a Prospective Observational Cohort Study on Psychedelic Use. <i>Journal of Medical Internet Research</i> , 2021, 23, e25973.	2.1	10
426	Psychedelic drug use and schizotypy in young adults. <i>Scientific Reports</i> , 2021, 11, 15058.	1.6	8
427	Systematized Review of Psychotherapeutic Components of Psilocybin-Assisted Psychotherapy. <i>American Journal of Psychotherapy</i> , 2021, 74, 140-149.	0.4	46
428	Losing the Self in Near-Death Experiences: The Experience of Ego-Dissolution. <i>Brain Sciences</i> , 2021, 11, 929.	1.1	14
429	Does Psychedelic Therapy Have a Transdiagnostic Action and Prophylactic Potential?. <i>Frontiers in Psychiatry</i> , 2021, 12, 661233.	1.3	41
430	Psilocybin Induces Aberrant Prediction Error Processing of Tactile Mismatch Responses: A Simultaneous EEG-fMRI Study. <i>Cerebral Cortex</i> , 2021, 32, 186-196.	1.6	15
432	Lysergic Acid Diethylamide, Psilocybin and Dimethyltryptamine in Depression Treatment: A Systematic Review. <i>Pharmaceuticals</i> , 2021, 14, 793.	1.7	13
433	Depression as a Disorder of Consciousness. <i>British Journal for the Philosophy of Science</i> , 0, , .	1.4	6

#	ARTICLE	IF	CITATIONS
434	Blinding and expectancy confounds in psychedelic randomized controlled trials. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 1133-1152.	1.3	133
435	Pharmacologic Similarities and Differences Among Hallucinogens. <i>Journal of Clinical Pharmacology</i> , 2021, 61, S100-S113.	1.0	4
436	Cancer Healthcare Workersâ€™ Perceptions toward Psychedelic-Assisted Therapy: A Preliminary Investigation. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 8160.	1.2	6
437	â€œThis Is Something That Changed My Lifeâ€ A Qualitative Study of Patients' Experiences in a Clinical Trial of Ketamine Treatment for Alcohol Use Disorders. <i>Frontiers in Psychiatry</i> , 2021, 12, 695335.	1.3	25
438	Use of alternative therapy with Psilocybin in oncologic patients with depression and/or anxiety disorders - integrative review. <i>Research, Society and Development</i> , 2021, 10, e568101019297.	0.0	0
439	The Role of Psilocybin-Assisted Psychotherapy to Support Patients With Cancer: A Critical Scoping Review of the Research. <i>Journal of Holistic Nursing</i> , 2021, , 089801012110390.	0.6	3
440	Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis. <i>Journal of Psychopharmacology</i> , 2022, 36, 20-30.	2.0	19
441	Evaluating the risk of psilocybin for the treatment of bipolar depression: A review of the research literature and published case studies. <i>Journal of Affective Disorders Reports</i> , 2021, 6, 100240.	0.9	13
442	Improving cognitive functioning in major depressive disorder with psychedelics: A dimensional approach. <i>Neurobiology of Learning and Memory</i> , 2021, 183, 107467.	1.0	20
443	Ancient Roots of Todayâ€™s Emerging Renaissance in Psychedelic Medicine. <i>Culture, Medicine and Psychiatry</i> , 2022, 46, 890-903.	0.7	11
444	A Qualitative Exploration of Relational Ethical Challenges and Practices in Psychedelic Healing. <i>Journal of Humanistic Psychology</i> , 0, , 002216782110452.	1.4	22
445	Rediscovering Psilocybin as an Antidepressive Treatment Strategy. <i>Pharmaceuticals</i> , 2021, 14, 985.	1.7	8
446	Co-design of Guidance for Patient and Public Involvement in Psychedelic Research. <i>Frontiers in Psychiatry</i> , 2021, 12, 727496.	1.3	8
447	Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience. <i>European Neuropsychopharmacology</i> , 2021, 50, 121-132.	0.3	57
448	New Insights Into the Clinical and Nonclinical Effects of Psychedelic Substances. <i>European Psychologist</i> , 0, , .	1.8	1
449	Classic psychedelics in the treatment of substance use disorder: Potential synergies with twelve-step programs. <i>International Journal of Drug Policy</i> , 2021, 98, 103380.	1.6	21
450	Dose effect of psilocybin on primary and secondary depression: a preliminary systematic review and meta-analysis. <i>Journal of Affective Disorders</i> , 2022, 296, 26-34.	2.0	29
451	Classical Psychedelics as Therapeutics in Psychiatry â€“ Current Clinical Evidence and Potential Therapeutic Mechanisms in Substance Use and Mood Disorders. <i>Pharmacopsychiatry</i> , 2021, 54, 176-190.	1.7	34

#	ARTICLE	IF	CITATIONS
452	Pharmacological assistance for psychotherapy. Emerging Trends in Drugs, Addictions, and Health, 2021, 1, 100017.	0.5	0
453	Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants. Psychopharmacology, 2021, 238, 341-354.	1.5	70
455	Targeting Mitochondrial Dysfunction for Bipolar Disorder. Current Topics in Behavioral Neurosciences, 2020, 48, 61-99.	0.8	10
456	Therapeutic Applications of Ayahuasca and Other Sacred Medicines. , 2014, , 1-21.		5
457	The History of Psychedelics in Medicine. , 2016, , 1-26.		16
458	Halluzinogene. , 2019, , 223-235.		1
459	Effects of acute and repeated treatment with serotonin 5-HT _{2A} receptor agonist hallucinogens on intracranial self-stimulation in rats.. Experimental and Clinical Psychopharmacology, 2019, 27, 215-226.	1.3	32
466	Efficacy of psychedelic treatments on depressive symptoms: A meta-analysis. Journal of Psychopharmacology, 2020, 34, 1079-1085.	2.0	52
467	Rapid-Acting Antidepressants. Current Pharmaceutical Design, 2018, 24, 2556-2563.	0.9	36
468	A Qualitative Report on the Subjective Experience of Intravenous Psilocybin Administered in an fMRI Environment. Current Drug Abuse Reviews, 2015, 7, 117-127.	3.4	39
469	Psilocybin-Occasioned Mystical Experiences in the Treatment of Tobacco Addiction. Current Drug Abuse Reviews, 2015, 7, 157-164.	3.4	306
470	Ketamine and Depression: A Review. International Journal of Transpersonal Studies, 2014, 33, 40-74.	0.2	4
471	Psychedelic drugsâ€”a new era inâ€”psychiatry?. Dialogues in Clinical Neuroscience, 2019, 21, 139-147.	1.8	70
472	¹⁴ C-Psilocin tissue distribution in pregnant rats after intravenous administration. Functional Foods in Health and Disease, 2014, 4, 232.	0.3	4
473	Was it a vision or a waking dream?. Frontiers in Psychology, 2014, 5, 255.	1.1	26
475	Homebrewed psilocybin: can new routes for pharmaceutical psilocybin production enable recreational use?. Bioengineered, 2021, 12, 8863-8871.	1.4	2
476	Schedule 1 barriers to research in the UK: An in-depth qualitative analysis. Drug Science, Policy and Law, 2021, 7, 205032452110493.	0.6	3
477	Psychedelics, Mystical Experiences, and Meaning Making: A Renegotiation Process With the Challenges of Existence. Journal of Humanistic Counseling, 2021, 60, 180-196.	0.3	8

#	ARTICLE	IF	CITATIONS
478	Psilocybin for End-of-Life Anxiety Symptoms: A Systematic Review and Meta-Analysis. <i>Psychiatry Investigation</i> , 2021, 18, 958-967.	0.7	13
479	Study Protocol for "Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study" <i>Frontiers in Psychiatry</i> , 2021, 12, 735523.	1.3	33
480	Classic Psychedelic Use and Mechanisms of Mental Health: Exploring the Mediating Roles of Spirituality and Emotion Processing on Symptoms of Anxiety, Depressed Mood, and Disordered Eating in a Community Sample. <i>Journal of Humanistic Psychology</i> , 0, , 002216782110480.	1.4	12
482	Lysergic Acid Diethylamide and Mescaline. , 0, , 135-152.		0
483	The Psychedelic Renaissance: Horizons, the Fifth Annual Conference on Psychedelic Research. <i>The Einstein Journal of Biology and Medicine: EJBM</i> , 2016, 28, 36.	0.2	0
484	Psilocybin as an alternative medicine for patients suffering from depression. <i>Psychiatria I Psychologia Kliniczna</i> , 2016, 16, 165-170.	0.3	1
485	Geschichte der Psychedelika in der Medizin. , 2017, , 1-29.		0
486	Psychedelika. , 2017, , 1-19.		0
487	Psycholytische Therapie. Leben wollen und sterben können. , 2017, , 311-326.		0
488	Geschichte der Psychedelika in der Medizin. , 2018, , 83-104.		0
489	Psychedelika. , 2018, , 669-682.		0
490	Legitimate Medicine in the Age of Consumerism. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
495	Mechanisms and Methods for Placing New Psychoactive Substances under Control. <i>Kriminologijos Studijos</i> , 0, 7, 27-55.	0.0	0
496	A potential role for psilocybin in the treatment of obsessive-compulsive disorder. <i>Journal of Psychedelic Studies</i> , 2020, 4, 77-87.	0.5	2
498	A narrative synthesis of research with 5-MeO-DMT. <i>Journal of Psychopharmacology</i> , 2022, 36, 273-294.	2.0	28
500	Baseline Power of Theta Oscillations Predicts Mystical-Type Experiences Induced by DMT in a Natural Setting. <i>Frontiers in Psychiatry</i> , 2021, 12, 720066.	1.3	9
504	Self-Medication for Chronic Pain Using Classic Psychedelics: A Qualitative Investigation to Inform Future Research. <i>Frontiers in Psychiatry</i> , 2021, 12, 735427.	1.3	15
505	Psychedelic-inspired approaches for treating neurodegenerative disorders. <i>Journal of Neurochemistry</i> , 2022, 162, 109-127.	2.1	17

#	ARTICLE	IF	CITATIONS
506	Hallucinogen-Related Disorders. <i>Psychiatry Update</i> , 2022, , 41-56.	0.1	0
507	Novel Treatment Approaches for Substance Use Disorders: Therapeutic Use of Psychedelics and the Role of Psychotherapy. <i>Current Addiction Reports</i> , 2022, 9, 48-58.	1.6	7
509	Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review. <i>Psychopharmacology</i> , 2022, 239, 15-33.	1.5	45
510	Psilocybin-assisted therapy for the treatment of resistant major depressive disorder (PsiDeR): protocol for a randomised, placebo-controlled feasibility trial. <i>BMJ Open</i> , 2021, 11, e056091.	0.8	7
511	Psychedelics and Hallucinogens in Psychiatry: Finding New Pharmacological Targets. <i>Current Topics in Medicinal Chemistry</i> , 2022, 22, 1250-1260.	1.0	3
513	Psychedelic Drugs. , 2021, , 1313-1320.		0
514	Psilocybin-assisted psychotherapy for depression: Emerging research on a psychedelic compound with a rich history. <i>Journal of the Neurological Sciences</i> , 2022, 434, 120096.	0.3	10
515	The Potential of Psychedelics for End of Life and Palliative Care. <i>Current Topics in Behavioral Neurosciences</i> , 2021, , 169-184.	0.8	8
516	Psychedelics as Novel Therapeutics in Alzheimer's Disease: Rationale and Potential Mechanisms. <i>Current Topics in Behavioral Neurosciences</i> , 2021, , 287-317.	0.8	11
517	The therapeutic potential of psychedelic substances in Hospice and Palliative Care. <i>Progress in Palliative Care</i> , 2022, 30, 1-3.	0.7	4
519	Assessing the risk-benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research. <i>Psychopharmacology</i> , 2022, 239, 1907-1932.	1.5	36
520	Acute sleep deprivation upregulates serotonin 2A receptors in the frontal cortex of mice via the immediate early gene Egr3. <i>Molecular Psychiatry</i> , 2022, 27, 1599-1610.	4.1	8
522	Lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes. <i>Journal of Psychopharmacology</i> , 2022, 36, 57-65.	2.0	22
523	Knowledge, Perceptions, and Use of Psychedelics among Individuals with Fibromyalgia. <i>Journal of Psychoactive Drugs</i> , 2023, 55, 73-84.	1.0	7
524	MDMA/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults. <i>Journal of Psychopharmacology</i> , 2022, 36, 46-56.	2.0	28
525	The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation. <i>Journal of Psychopharmacology</i> , 2022, 36, 114-125.	2.0	47
526	Psilocybin use is associated with lowered odds of crime arrests in US adults: A replication and extension. <i>Journal of Psychopharmacology</i> , 2022, 36, 66-73.	2.0	16
527	Potential of chromatography and mass spectrometry for the differentiation of three series of positional isomers of 2-(dimethoxyphenyl)-N-(2-halogenobenzyl)ethanamines. <i>Drug Testing and Analysis</i> , 2022, 14, 1102-1115.	1.6	2

#	ARTICLE	IF	CITATIONS
528	Psilocybin for Treating Psychiatric Disorders: A Psychonaut Legend or a Promising Therapeutic Perspective?. <i>Journal of Xenobiotics</i> , 2022, 12, 41-52.	2.9	10
529	The Therapeutic Potential of Psychedelic-assisted Therapies for Symptom Control in Patients Diagnosed With Serious Illness: A Systematic Review. <i>Journal of Pain and Symptom Management</i> , 2022, 63, e725-e738.	0.6	15
530	Diversity, biology, and history of psilocybin-containing fungi: Suggestions for research and technological development. <i>Fungal Biology</i> , 2022, 126, 308-319.	1.1	32
531	Analysis of Psilocybin-Assisted Therapy in Medicine: A Narrative Review. <i>Cureus</i> , 2022, 14, e21944.	0.2	3
532	The clinical pharmacology and potential therapeutic applications of 5- <i>N,N</i> -dimethyltryptamine (5-MeO-DMT). <i>Journal of Neurochemistry</i> , 2022, 162, 128-146.	2.1	31
533	Psychedelic Therapy's Transdiagnostic Effects: A Research Domain Criteria (RDoC) Perspective. <i>Frontiers in Psychiatry</i> , 2021, 12, 800072.	1.3	35
535	Can psilocybin be safely administered under medical supervision? A systematic review of adverse event reporting in clinical trials. <i>Drug Science, Policy and Law</i> , 2022, 8, 205032452210852.	0.6	16
536	Human behavioral pharmacology of psychedelics. <i>Advances in Pharmacology</i> , 2022, 93, 105-132.	1.2	6
537	Ketamine for Depression: Advances in Clinical Treatment, Rapid Antidepressant Mechanisms of Action, and a Contrast with Serotonergic Psychedelics. <i>Current Topics in Behavioral Neurosciences</i> , 2022, , 141-167.	0.8	4
538	Hallucinogenic drugs and their potential for treating fear-related disorders: Through the lens of fear extinction. <i>Journal of Neuroscience Research</i> , 2022, 100, 947-969.	1.3	8
539	The Use of Psilocybin in the Treatment of Psychiatric Disorders with Attention to Relative Safety Profile: A Systematic Review. <i>Journal of Psychoactive Drugs</i> , 2023, 55, 40-50.	1.0	29
540	Trajectory of Antidepressant Effects after Single- or Two-Dose Administration of Psilocybin: A Systematic Review and Multivariate Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 938.	1.0	17
541	Micro-dosing psychedelics as a plausible adjunct to psychosexual and couple's therapy: a qualitative insight. <i>Sexual and Relationship Therapy</i> , 0, , 1-14.	0.7	0
543	The therapeutic potential of psilocybin: a systematic review. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 833-840.	1.0	14
544	Repeated lysergic acid diethylamide (LSD) reverses stress-induced anxiety-like behavior, cortical synaptogenesis deficits and serotonergic neurotransmission decline. <i>Neuropsychopharmacology</i> , 2022, 47, 1188-1198.	2.8	36
545	Top Ten Tips Palliative Care Clinicians Should Know About Psychedelic-Assisted Therapy in the Context of Serious Illness. <i>Journal of Palliative Medicine</i> , 2022, 25, 1273-1281.	0.6	8
546	The Acceptance/Avoidance-Promoting Experiences Questionnaire (APEQ): A theory-based approach to psychedelic drugs' effects on psychological flexibility. <i>Journal of Psychopharmacology</i> , 2022, 36, 387-408.	2.0	19
548	Effects of Naturalistic Psychedelic Use on Depression, Anxiety, and Well-Being: Associations With Patterns of Use, Reported Harms, and Transformative Mental States. <i>Frontiers in Psychiatry</i> , 2022, 13, 831092.	1.3	20

#	ARTICLE	IF	CITATIONS
549	Using Psychedelics in Clinical Practice: Comparing Therapeutic Uses and Potential Harms. <i>Current Reviews in Clinical and Experimental Pharmacology</i> , 2023, 18, 94-109.	0.4	1
550	Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression. <i>Frontiers in Pharmacology</i> , 2021, 12, 788155.	1.6	77
551	Psilocybin-Induced Mystical-Type Experiences are Related to Persisting Positive Effects: A Quantitative and Qualitative Report. <i>Frontiers in Pharmacology</i> , 2022, 13, 841648.	1.6	29
552	A systematic literature review and meta-analysis of the effect of psilocybin and methylenedioxymethamphetamine on mental, behavioural or developmental disorders. <i>Australian and New Zealand Journal of Psychiatry</i> , 2023, 57, 362-378.	1.3	12
553	Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trials. <i>Psychopharmacology</i> , 2022, 239, 1989-2010.	1.5	70
554	Can the revival of serotonergic psychedelic drugs as treatments for mental disorders help to characterize their risks and benefits?. <i>Expert Opinion on Drug Safety</i> , 2022, , 1-4.	1.0	2
556	Palliative care provider attitudes toward existential distress and treatment with psychedelic-assisted therapies. <i>BMC Palliative Care</i> , 2021, 20, 191.	0.8	10
557	The phosphate ester group in secondary metabolites. <i>Natural Product Reports</i> , 2022, 39, 1066-1107.	5.2	9
558	Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 761-776.	1.0	13
566	Classical hallucinogens as antidepressant drugs: A cautionary approach. <i>Current Neuropharmacology</i> , 2022, 20, .	1.4	0
567	Using a MDMA- and LSD-Group Therapy Model in Clinical Practice in Switzerland and Highlighting the Treatment of Trauma-Related Disorders. <i>Frontiers in Psychiatry</i> , 2022, 13, 863552.	1.3	21
568	The Effects of Psilocybin in Adults with Major Depressive Disorder and the General Population: Findings from Neuroimaging Studies. <i>Psychiatry Research</i> , 2022, 313, 114577.	1.7	2
569	The efficacy of psilocybin in the treatment of depression and anxiety: A meta-analysis. <i>Current Psychiatry Research and Reviews</i> , 2022, 18, .	0.1	0
570	Psychedelic resting-state neuroimaging: A review and perspective on balancing replication and novel analyses. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 138, 104689.	2.9	45
571	If the Doors of Perception Were Cleansed, Would Chronic Pain be Relieved? Evaluating the Benefits and Risks of Psychedelics. <i>Journal of Pain</i> , 2022, 23, 1666-1679.	0.7	8
572	Postpartum depression: A role for psychedelics?. <i>Journal of Psychopharmacology</i> , 2022, 36, 920-931.	2.0	2
573	Psychoactive Drugs in the Management of Post Traumatic Stress Disorder: A Promising New Horizon. <i>Cureus</i> , 2022, , .	0.2	1
574	Review of potential psychedelic treatments for PTSD. <i>Journal of the Neurological Sciences</i> , 2022, 439, 120302.	0.3	10

#	ARTICLE	IF	CITATIONS
575	Models of Psychedelic-Assisted Psychotherapy: A Contemporary Assessment and an Introduction to EMBARK, a Transdiagnostic, Trans-Drug Model. <i>Frontiers in Psychology</i> , 2022, 13, .	1.1	24
576	Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder. <i>Neuropsychopharmacology</i> , 2022, 47, 1854-1862.	2.8	64
577	Classic Psychedelics in Addiction Treatment: The Case for Psilocybin in Tobacco Smoking Cessation. <i>Current Topics in Behavioral Neurosciences</i> , 2022, , 213-227.	0.8	10
578	Neural mechanisms underlying psilocybin's therapeutic potential – the need for preclinical in vivo electrophysiology. <i>Journal of Psychopharmacology</i> , 2022, 36, 781-793.	2.0	13
579	Psychedelic Microdosing, Mindfulness, and Anxiety: A Cross-Sectional Mediation Study. <i>Journal of Psychoactive Drugs</i> , 2023, 55, 310-320.	1.0	3
581	Acute behavioral and Neurochemical Effects of Novel <i>N</i> -Benzyl-2-Phenylethylamine Derivatives in Adult Zebrafish. <i>ACS Chemical Neuroscience</i> , 2022, 13, 1902-1922.	1.7	4
582	Psychedelic-Assisted Psychotherapy – A Systematic Review of Associated Psychological Interventions. <i>Frontiers in Psychology</i> , 0, 13, .	1.1	17
583	Three Naturally-Occurring Psychedelics and Their Significance in the Treatment of Mental Health Disorders. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
584	Mysticizing medicine: incorporating nondualism into the training of psychedelic guides. <i>Interdisciplinary Science Reviews</i> , 2023, 48, 752-767.	1.0	1
585	Potential benefits and harms: a review of poisonous mushrooms in the world. <i>Fungal Biology Reviews</i> , 2022, 42, 56-68.	1.9	8
586	Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy. <i>CNS Spectrums</i> , 2023, 28, 416-426.	0.7	6
587	Decreases in State and Trait Anxiety Post-psilocybin: A Naturalistic, Observational Study Among Retreat Attendees. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	5
588	The promises and pitfalls of facilitated spiritual experiences for the study of religion. <i>Religion, Brain and Behavior</i> , 0, , 1-7.	0.4	0
589	Psychedelic drugs for psychiatric disorders. <i>Journal of the Neurological Sciences</i> , 2022, 440, 120332.	0.3	3
590	Psychedelic-assisted psychotherapy to treat psychiatric and existential distress in life-threatening medical illnesses and palliative care. <i>Neuropharmacology</i> , 2022, 216, 109174.	2.0	18
591	Psychedelics, Atheism, and Naturalism Myth and Reality. <i>Journal of Consciousness Studies</i> , 2022, 29, 69-92.	0.4	1
592	The illusion of knowledge in the emerging field of psychedelic research. <i>New Ideas in Psychology</i> , 2022, 67, 100967.	1.2	5
593	Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review. <i>Journal of Psychopharmacology</i> , 2022, 36, 1100-1117.	2.0	54

#	ARTICLE	IF	CITATIONS
594	Experiences With Sacred Mushrooms and Psilocybin In Dialogue: Transdisciplinary Interpretations Of The "Velada". <i>Anthropology of Consciousness</i> , 2022, 33, 385-411.	0.5	1
595	Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample. <i>Journal of Psychopharmacology</i> , 2022, 36, 932-942.	2.0	34
596	Cystathionine Gamma-Lyase Regulate Psilocybin Biosynthesis in <i>Gymnopilus dilepis</i> Mushroom via Amino Acid Metabolism Pathways. <i>Journal of Fungi (Basel, Switzerland)</i> , 2022, 8, 870.	1.5	0
597	Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder. <i>JAMA Psychiatry</i> , 2022, 79, 953.	6.0	217
598	Comparison of psychedelic and near-death or other non-ordinary experiences in changing attitudes about death and dying. <i>PLoS ONE</i> , 2022, 17, e0271926.	1.1	11
599	Serotonin 5-HT _{2A} , 5-HT _{2c} and 5-HT _{1A} receptor involvement in the acute effects of psilocybin in mice. In vitro pharmacological profile and modulation of thermoregulation and head-twitch response. <i>Biomedicine and Pharmacotherapy</i> , 2022, 154, 113612.	2.5	22
600	An Interpretative Phenomenological Analysis of the use of psilocybin by veterans with symptoms of trauma. <i>Drug Science, Policy and Law</i> , 2022, 8, 205032452211241.	0.6	4
601	Coming clean: Saying "know" to drugs " Part I. <i>South African General Practitioner</i> , 2022, 3, 55-58.	0.0	0
602	Macro dosing to micro dosing with psychedelics: Clinical, social, and cultural perspectives. <i>Transcultural Psychiatry</i> , 2022, 59, 665-674.	0.9	4
603	A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic Review. <i>CNS Drugs</i> , 2022, 36, 1031-1047.	2.7	5
604	Ketamine With Psychotherapy for the Treatment of Depression. <i>Psychiatric Annals</i> , 2022, 52, 371-374.	0.1	0
605	The Safety and Efficacy of Psychedelic-Assisted Therapies for Older Adults: Knowns and Unknowns. <i>American Journal of Geriatric Psychiatry</i> , 2023, 31, 44-53.	0.6	10
606	The use of classic psychedelics among adults: a Danish online survey study. <i>Nordic Journal of Psychiatry</i> , 2023, 77, 367-378.	0.7	5
607	The psychedelic escape from depression. <i>Nature</i> , 2022, 609, S87-S89.	13.7	5
608	Bespoke library docking for 5-HT _{2A} receptor agonists with antidepressant activity. <i>Nature</i> , 2022, 610, 582-591.	13.7	99
609	Being no one, being One: The role of ego-dissolution and connectedness in the therapeutic effects of psychedelic experience. <i>Journal of Psychedelic Studies</i> , 2022, 6, 111-136.	0.5	4
610	Facing death, returning to life: A qualitative analysis of MDMA-assisted therapy for anxiety associated with life-threatening illness. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	4
611	Heads, Seekers, Psychonauts, and One-Timers: Patterns in Stories of Psychedelic Consumption. <i>Journal of Drug Issues</i> , 2023, 53, 402-421.	0.6	3

#	ARTICLE	IF	CITATIONS
612	Lysergic Acid Diethylamideâ€œAssisted Therapy in Patients With Anxiety With and Without a Life-Threatening Illness: A Randomized, Double-Blind, Placebo-Controlled Phase II Study. <i>Biological Psychiatry</i> , 2023, 93, 215-223.	0.7	79
613	Psychedelic-Assisted Therapies in Patients With Serious Illness: Opportunities and Challenges. <i>Psychiatric Annals</i> , 2022, 52, 359-364.	0.1	1
614	Ketamine-assisted meaning-centered psychotherapy for a patient with severe suicidal behavior. <i>Palliative and Supportive Care</i> , 2023, 21, 362-364.	0.6	1
615	Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis. <i>Journal of Affective Disorders</i> , 2023, 322, 194-204.	2.0	20
616	A Critical Appraisal of Evidence on the Efficacy and Safety of Serotonergic Psychedelic Drugs as Emerging Antidepressants. <i>Journal of Clinical Psychopharmacology</i> , 2022, 42, 581-588.	0.7	7
617	Hallucinogenic Drugs. , 2022, , 267-298.		0
618	Lasting increases in trait mindfulness after psilocybin correlate positively with the mystical-type experience in healthy individuals. <i>Frontiers in Psychology</i> , 0, 13, .	1.1	11
619	A century of research on psychedelics: A scientometric analysis on trends and knowledge maps of hallucinogens, entactogens, enteogens and dissociative drugs. <i>European Neuropsychopharmacology</i> , 2022, 64, 44-60.	0.3	13
620	Psilocybin-assisted therapy for reducing alcohol intake in patients with alcohol use disorder: protocol for a randomised, double-blinded, placebo-controlled 12-week clinical trial (The QUANTUM) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5		
621	Therapeutic (Sub)stance: Current practice and therapeutic conduct in preparatory sessions in substance-assisted psychotherapyâ€œA systematized review. <i>Journal of Psychopharmacology</i> , 2022, 36, 1191-1207.	2.0	7
622	Study protocol for â€œMDMA-assisted therapy as a treatment for major depressive disorder: A proof of principle studyâ€œ. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	1
623	Bibliometric Analysis of Academic Journal Articles Reporting Results of Psychedelic Clinical Studies. <i>Journal of Psychoactive Drugs</i> , 2023, 55, 434-444.	1.0	1
624	Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA and psilocybin) and psychological distress and suicidality. <i>Scientific Reports</i> , 2022, 12, .	1.6	16
625	The neural basis of psychedelic action. <i>Nature Neuroscience</i> , 2022, 25, 1407-1419.	7.1	85
626	Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. <i>New England Journal of Medicine</i> , 2022, 387, 1637-1648.	13.9	304
627	Psilocybin for alcohol use disorder: Rationale and design considerations for a randomized controlled trial. <i>Contemporary Clinical Trials</i> , 2022, 123, 106976.	0.8	3
628	Psilocybin containing mushrooms: a rapidly developing biotechnology industry in the psychiatry, biomedical and nutraceutical fields. <i>3 Biotech</i> , 2022, 12, .	1.1	2
629	Mushrooms, psilocybin. , 2024, , 567-569.		0

#	ARTICLE	IF	CITATIONS
630	Ketanserin Reverses the Acute Response to LSD in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Participants. <i>International Journal of Neuropsychopharmacology</i> , 2023, 26, 97-106.	1.0	27
631	Body mass index (BMI) does not predict responses to psilocybin. <i>Journal of Psychopharmacology</i> , 2023, 37, 107-116.	2.0	2
632	Music programming for psilocybin-assisted therapy: Guided Imagery and Music-informed perspectives. <i>Frontiers in Psychology</i> , 0, 13, .	1.1	6
633	Psilocybin-assisted therapy improves psycho-social-spiritual well-being in cancer patients. <i>Journal of Affective Disorders</i> , 2023, 323, 592-597.	2.0	27
634	Experimental strategies to discover and develop the next generation of psychedelics and entactogens as medicines. <i>Neuropharmacology</i> , 2023, 225, 109375.	2.0	6
635	ŁŁ•ŁŁ•Ł;ŁŁŁ; ŁŸŁ;Ł•ŁŸŁŁ”Ł•Ł•Ł†Ł\$ĐĐžĐ† Đ•Đ•ĐĐĐŸĐ†Đ† Đ•Đ•Đ†Đ† Đ—ĐĐĐ\$Đ•ĐĐĐ”Đ•Đ•Đ- ĐŁĐ\$ĐĐĐ†ĐĐ”. <i>Likarska Sprawa</i> , 2022, 13, .		
636	The Altered States Database: Psychometric data from a systematic literature review. <i>Scientific Data</i> , 2022, 9, .	2.4	7
637	Reactivations after 5-methoxy-N,N-dimethyltryptamine use in naturalistic settings: An initial exploratory analysis of the phenomenon’s predictors and its emotional valence. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	5
638	Psilocybin mushrooms for psychological and existential distress. <i>Canadian Family Physician</i> , 2022, 68, 823-827.	0.1	2
639	Effect of lysergic acid diethylamide (LSD) on reinforcement learning in humans. <i>Psychological Medicine</i> , 2023, 53, 6434-6445.	2.7	17
640	Exploratory investigation of a patient’s informed low-dose psilocybin pulse regimen in the suppression of cluster headache: Results from a randomized, double-blind, placebo-controlled trial. <i>Headache</i> , 2022, 62, 1383-1394.	1.8	13
641	Therapeutic use of psilocybin: Practical considerations for dosing and administration. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	13
642	Psychedelics and fNIRS neuroimaging: exploring new opportunities. <i>Neurophotonics</i> , 2022, 10, .	1.7	5
643	In Becoming. Instability of Psychedelic Substances. <i>Etnografia Polska</i> , 2022, 66, 29-46.	0.0	0
644	Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: A case report. <i>Heliyon</i> , 2022, 8, e12135.	1.4	3
645	“A sense of the bigger picture:” A qualitative analysis of follow-up interviews with people with bipolar disorder who self-reported psilocybin use. <i>PLoS ONE</i> , 2022, 17, e0279073.	1.1	4
646	Subtypes of the psychedelic experience have reproducible and predictable effects on depression and anxiety symptoms. <i>Journal of Affective Disorders</i> , 2023, 324, 239-249.	2.0	7
647	The Question. , 2023, , 3-24.		0

#	ARTICLE	IF	CITATIONS
648	Therapeutic uses of psychedelics for eating disorders and body dysmorphic disorder. <i>Journal of Psychopharmacology</i> , 2023, 37, 3-13.	2.0	3
649	Psychedelic innovations and the crisis of psychopharmacology. <i>BioSocieties</i> , 0, , .	0.8	5
650	Associations between MDMA/ecstasy, classic psychedelics, and suicidal thoughts and behaviors in a sample of U.S. adolescents. <i>Scientific Reports</i> , 2022, 12, .	1.6	5
651	Hopelessness, Suicidality, and Co-Occurring Substance Use among Adolescent Hallucinogen Usersâ€™A National Survey Study. <i>Children</i> , 2022, 9, 1906.	0.6	0
652	Risks and benefits of psilocybin use in people with bipolar disorder: An international web-based survey on experiences of â€˜magic mushroomâ€™™ consumption. <i>Journal of Psychopharmacology</i> , 2023, 37, 49-60.	2.0	24
653	Lower-dose psycholytic therapy â€˜ A neglected approach. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	13
654	Research into Psychedelic-Assisted Psychotherapy for Anorexia Nervosa Should be Funded. <i>Journal of Bioethical Inquiry</i> , 0, , .	0.9	1
655	Probing the antidepressant potential of psilocybin: integrating insight from human research and animal models towards an understanding of neural circuit mechanisms. <i>Psychopharmacology</i> , 2023, 240, 27-40.	1.5	5
656	Entheogenic Spirituality: Characteristics of Spiritually Motivated Psychedelics Use. <i>International Journal for the Psychology of Religion, The</i> , 0, , 1-17.	1.3	1
657	An Integrative Review of Measures of Spirituality in Experimental Studies of Psilocybin in Serious Illness Populations. <i>American Journal of Hospice and Palliative Medicine</i> , 0, , 104990912211477.	0.8	0
658	Alleviating anxiety and taming trauma: Novel pharmacotherapeutics for anxiety disorders and posttraumatic stress disorder. <i>Neuropharmacology</i> , 2023, 226, 109418.	2.0	15
659	Opening Deathâ€™™s Door: Psilocybin and Existential Suffering in Palliative Care. <i>Philosophy and Medicine</i> , 2023, , 235-262.	0.3	0
660	Psychedelics for Patients With Cancer: A Comprehensive Literature Review. <i>Annals of Pharmacotherapy</i> , 2023, 57, 1062-1075.	0.9	2
662	Are psychedelics the answer to chronic pain: A review of current literature. <i>Pain Practice</i> , 2023, 23, 447-458.	0.9	6
663	Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment. <i>Neuropharmacology</i> , 2023, 226, 109422.	2.0	16
664	Psilocybin for Depression: From Credibility to Feasibility, Whatâ€™™s Missing?. <i>Pharmaceuticals</i> , 2023, 16, 68.	1.7	5
665	The Outline of Communal â€˜Ars Moriendiâ€™™ in Egalitarian Transhumanism. <i>Ethics in Progress</i> , 2023, 13, 25-41.	0.1	0
666	The costs and benefits of psychedelics on cognition and mood. <i>Neuron</i> , 2023, 111, 614-630.	3.8	7

#	ARTICLE	IF	CITATIONS
667	A non-hallucinogenic LSD analog with therapeutic potential for mood disorders. <i>Cell Reports</i> , 2023, 42, 112203.	2.9	28
668	Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. <i>Journal of Affective Disorders</i> , 2023, 327, 120-127.	2.0	32
669	Examining associations between MDMA/ecstasy and classic psychedelic use and impairments in social functioning in a U.S. adult sample. <i>Scientific Reports</i> , 2023, 13, .	1.6	1
670	Acute psilocybin enhances cognitive flexibility in rats. <i>Neuropsychopharmacology</i> , 2023, 48, 1011-1020.	2.8	11
671	Alkaloids from Fungi. , 2023, , 529-554.		0
672	Psychedelic replications in virtual reality and their potential as a therapeutic instrument: an open-label feasibility study. <i>Frontiers in Psychiatry</i> , 0, 14, .	1.3	4
673	Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020. <i>Journal of Psychopharmacology</i> , 2023, 37, 733-748.	2.0	8
674	Restructuring insight: An integrative review of insight in problem-solving, meditation, psychotherapy, delusions and psychedelics. <i>Consciousness and Cognition</i> , 2023, 110, 103494.	0.8	7
675	The Impact of Psychedelic Drugs on Anxiety and Depression in Advanced Cancer or other Life-threatening Disease. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 0, Publish Ahead of Print, .	0.6	2
676	Examining the Rationale for Studying Psychedelic-Assisted Psychotherapy for the Treatment of Caregiver Distress. , 0, , .		0
677	Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial. <i>Journal of Psychopharmacology</i> , 2023, 37, 698-706.	2.0	43
678	Neural Network Modulation of Ayahuasca: A Systematic Review of Human Studies. , 2023, 2, 76-91.		0
679	Clinical pharmacological innovation in the treatment of depression. <i>Expert Review of Clinical Pharmacology</i> , 2023, 16, 349-362.	1.3	7
680	Are psychedelic medicines the reset for chronic pain? Preliminary findings and research needs. <i>Neuropharmacology</i> , 2023, 233, 109528.	2.0	7
681	Predictors of Medical Studentsâ€™ Perceptions of Psilocybin-Assisted Therapy for Use in Medical Practice. <i>Cureus</i> , 2023, , .	0.2	3
682	G protein coupled receptors as targets for transformative neuropsychiatric therapeutics. <i>American Journal of Physiology - Cell Physiology</i> , 0, , .	2.1	1
683	Increased low-frequency brain responses to music after psilocybin therapy for depression. <i>Journal of Affective Disorders</i> , 2023, 333, 321-330.	2.0	5
713	The Health and Clinical Benefits of Medicinal Fungi. <i>Advances in Biochemical Engineering/Biotechnology</i> , 2023, , .	0.6	0

#	ARTICLE	IF	CITATIONS
715	The Potential for Psychedelics to Improve Coping Skills and Resilience in Persons With Newly Diagnosed Mild Cognitive Impairment or Early Alzheimer's Disease. <i>Current Geriatrics Reports</i> , 2023, 12, 149-155.	1.1	1
722	The role of neurotrophic factors in novel, rapid psychiatric treatments. <i>Neuropsychopharmacology</i> , 2024, 49, 227-245.	2.8	6
725	Preclinical models of treatment-resistant depression: challenges and perspectives. <i>Pharmacological Reports</i> , 2023, 75, 1326-1340.	1.5	0
744	Cardiovascular safety of psychedelic medicine: current status and future directions. <i>Pharmacological Reports</i> , 0, , .	1.5	1
747	The possible place for psychedelics in pharmacotherapy of mental disorders. <i>Pharmacological Reports</i> , 2023, 75, 1313-1325.	1.5	2
748	Mindfulness meditation and psychedelics: potential synergies and commonalities. <i>Pharmacological Reports</i> , 2023, 75, 1398-1409.	1.5	1
759	What Treatments Are Effective for Depression in Palliative Care Settings?. , 2023, , 204-218.		0
781	A Systematic Review of Interventions for Demoralization in Patients with Chronic Diseases. <i>International Journal of Behavioral Medicine</i> , 0, , .	0.8	0
791	Bringing It Home and Carrying It Forward. , 2024, , 252-262.		0
793	Integration Sessions. , 2024, , 204-251.		0
794	INTRODUCTION: A New Approach for the Whole Person. , 2024, , 1-9.		0
795	An Overview of Psychedelic-Assisted Therapy. , 2024, , 10-30.		0
798	Medicine Sessions. , 2024, , 167-203.		0
800	Preparation Sessions. , 2024, , 132-166.		0
801	Considerations Prior to Meeting With a Participant. , 2024, , 93-131.		0
802	EMBARK Mechanisms of Change in the Treatment of Depression. , 2024, , 70-92.		0
803	Introduction to the EMBARK Approach. , 2024, , 31-69.		0